

| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | | Attorney's Docket No. 17248-004002 | | Application No. 10/849,664 | |
|---|--------------|--|---------------------|---------------------------------------|-------|-------------------------------|-------------------------------|
| List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | | | | Applicant Szalay, et al. | | | |
| | | | | Filing Date May 19, 2004 | | Group Art Unit 1632 / 633 | |
| U.S. Patent Documents | | | | | | | |
| Examiner Initial | Desig. ID | Document Number | Publication Date | Patentee | Class | Subclass | Filing Date If Appropriate |
| RUK | A | 2003/0228261 | 12/11/03 | Szalay et al. | 424 | 9.34 | 06/05/02 |
| | B | 2003/0213007 | 11/13/03 | Slattery et al. | 800 | 15 | 03/26/03 |
| | C | 2002/0160970 | 10/31/02 | Hadlaczky et al. | 514 | 44 | 03/05/01 |
| | D | 2002/0160410 | 10/31/02 | Hadlaczky et al. | 435 | 6 | 04/17/02 |
| | E | 2004/0143861 | 07/22/04 | Hadlaczky et al. | 800 | 14 | 02/18/04 |
| | F | 2003/0133949 | 07/17/03 | Szalay et al. | 424 | 200.1 | 01/30/03 |
| | G | 2003/0101480 | 05/29/03 | Hadlaczky et al. | 800 | 278 | 11/01/02 |
| | H | 2003/0083293 | 05/01/03 | Hadlaczky et al. | 514 | 44 | 05/16/02 |
| | I | 2003/0059400 | 03/27/03 | Szalay | 424 | 93.2 | 07/03/02 |
| | J | 2003/0033617 | 02/13/03 | Hadlaczky et al. | 800 | 6 | 04/17/01 |
| | K | 2001/0029023 | 10/11/01 | Szalay et al. | 435 | 7.1 | 01/25/01 |
| | L | 2001/0008025 | 07/12/01 | Hadlaczky et al. | 800 | 8 | 06/12/98 |
| | M | 4,442,203 | 04/10/84 | Varshavsky | 435 | 6 | 06/30/81 |
| | N | 4,778,759 | 10/18/88 | Szalay et al. | 435 | 477 | 01/09/85 |
| | O | 5,221,623 | 06/22/93 | Legocki et al. | 435 | 252.3 | 07/19/89 |
| | P | 5,283,187 | 02/01/94 | Aebischer et al. | 435 | 182 | 01/08/91 |
| | Q | 5,300,436 | 04/05/94 | Goldstein et al. | 435 | 190 | 01/26/93 |
| | R | 5,550,050 | 08/27/96 | Holland et al. | 435 | 382 | 04/15/94 |
| | S | 5,639,275 | 06/17/97 | Baetge et al. | 604 | 891.1 | 05/25/95 |
| | T | 5,650,148 | 07/22/97 | Gage et al. | 424 | 93.2 | 03/10/94 |
| | U | 5,653,975 | 08/05/97 | Baetge et al. | 424 | 93.1 | 05/25/95 |
| | V | 5,656,481 | 08/12/97 | Baetge et al. | 435 | 325 | 05/25/95 |
| | W | 5,676,943 | 10/14/97 | Baetge et al. | 424 | 93.21 | 05/25/95 |
| | X | 5,704,910 | 01/06/98 | Humes | 604 | 502 | 06/05/95 |
| | Y | 5,750,103 | 05/12/98 | Cherksey | 424 | 93.21 | 06/02/95 |
| V | Z | 5,756,455 | 05/26/98 | Kinzler et al. | 514 | 12 | 02/17/95 |
| RUK | AA | 5,762,959 | 06/09/98 | Soon-Shiong et al. | 424 | 451 | 12/23/94 |

Examiner Signature

Robert J. Kelly

Date Considered

6/2/06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | | Attorney's Docket No. 17248-004002 | | Application No. 10/849,664 | |
|---|--------------|--|---------------------|---------------------------------------|---------------|--|-------------------------------|
| List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | | | | Applicant Szalay, et al. | | | |
| | | | | Filing Date May 19, 2004 | | Group Art Unit 1632 1633 | |
| U.S. Patent Documents | | | | | | | |
| Examiner Initial | Desig. ID | Document Number | Publication Date | Patentee | Class | Subclass | Filing Date If Appropriate |
| <i>DK</i> <div style="border-left: 1px solid black; height: 100%; width: 10px; margin: 0 auto;"></div> | AB | 5,795,790 | 08/18/98 | Schinstine et al. | 435 | 382 | 05/23/95 |
| | AC | 5,798,113 | 08/25/98 | Dionne et al. | 424 | 422 | 05/24/95 |
| | AD | 5,800,828 | 09/01/98 | Dionne et al. | 424 | 422 | 01/10/94 |
| | AE | 5,800,829 | 09/01/98 | Dionne et al. | 424 | 422 | 05/24/95 |
| | AF | 5,833,979 | 11/10/98 | Schinstine et al. | 424 | 93.21 | 05/23/95 |
| | AG | 5,834,001 | 10/10/98 | Dionne et al. | 424 | 422 | 05/24/95 |
| | AH | 5,837,234 | 11/17/98 | Gentile et al. | 424 | 93.7 | 06/07/95 |
| | AI | 5,840,576 | 11/24/98 | Schinstine et al. | 435 | 325 | 05/23/95 |
| | AJ | 5,842,431 | 12/01/98 | Wu | 112 | 232 | 02/19/97 |
| | AK | 5,853,385 | 12/29/98 | Emerich et al. | 604 | 500 | 08/26/94 |
| | AL | 5,853,717 | 12/29/98 | Schinstine et al. | 424 | 93.21 | 05/23/95 |
| | AM | 5,861,290 | 01/19/99 | Goldsmith et al. | 435 | 456 | 10/22/92 |
| | AN | 5,976,796 | 11/02/99 | Szalay et al. | 435 | 6 | 12/23/96 |
| | AO | 6,025,155 | 02/15/00 | Hadlaczky et al. | 435 | 69.1 | 08/07/96 |
| | AP | 6,077,697 | 06/20/00 | Hadlaczky et al. | 435 | 172.3 | 07/15/96 |
| | AQ | 6,080,849 | 06/27/00 | Bermudes et al. | 536 | 23.7 | 09/10/97 |
| | AR | 6,217,847 | 04/17/01 | Contag et al. | 424 | 9.1 | 01/19/99 |
| | AS | 6,265,557 | 07/24/01 | Diamond et al. | 536 | 23.1 | 05/09/97 |
| | AT | 6,511,967 | 01/28/03 | Weissleder et al. | 514 | 44 | 04/21/00 |
| | ✓ | AU | 6,713,293 | 03/30/04 | Grummt et al. | 435 | 182 |
| <i>DK</i> | AV | 6,743,967 | 06/01/04 | Hadlaczky et al. | 800 | 25 | 06/12/98 |

| Foreign Patent Documents or Published Foreign Patent Applications | | | | | | | | |
|---|--------------|--------------------|---------------------|-----------------------------|-------|----------|-------------|----|
| Examiner Initial | Desig. ID | Document Number | Publication Date | Country or Patent Office | Class | Subclass | Translation | |
| | | | | | | | Yes | No |
| <i>DK</i> | AW | 00/47237 | 08/17/00 | PCT | | | | |
| <i>DK</i> | AX | 01/05229 | 1/25/01 | PCT | | | | |
| <i>DK</i> | AY | 01/14579 | 03/01/01 | PCT | | | | |

| | |
|---|-------------------------------|
| Examiner Signature <i>Robert A. Kelly</i> | Date Considered <i>6/2/06</i> |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

| | | | |
|---|--|---------------------------------------|--|
| Substitute Form PTO-1449 (Modified) | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 17248-004002 | Application No. 10/849,664 |
| List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | | Applicant Szalay, et al. | |
| | | Filing Date May 19, 2004 | Group Art Unit 1632 1633 |

| Foreign Patent Documents or Published Foreign Patent Applications | | | | | | | | |
|---|--------------|--------------------|---------------------|-----------------------------|-------|----------|-------------|----|
| Examiner Initial | Desig. ID | Document Number | Publication Date | Country or Patent Office | Class | Subclass | Translation | |
| | | | | | | | Yes | No |
| <i>MLK</i> | AZ | 01/18195 | 03/15/01 | PCT | | | | |
| | BA | 01/25399 | 04/12/01 | PCT | | | | |
| | BB | 03/014380 | 02/20/03 | PCT | | | | |
| | BC | 03/063593 | 08/07/03 | PCT | | | | |
| | BD | 03/104485 | 12/18/03 | PCT A2 | | | | |
| | BE | 1 281 767 | 05/28/03 | EP | | | | |
| | BF | 1 281 772 | 02/05/03 | EP A1 | | | | |
| | BG | 1 369 491 | 12/10/03 | EP | | | | |
| | BH | 91/07989 | 06/13/91 | PCT | | | | |
| <i>MLK</i> | BI | 94/10302 | 05/11/94 | PCT | | | | X* |

X* = An English Language Derwent abstract is being provided

| Other Documents (include Author, Title, Date, and Place of Publication) | | |
|---|--------------|--|
| Examiner Initial | Desig. ID | Document |
| <i>MLK</i> | BJ | Advisory Committee on Immunization Practices (ACIP), "Smallpox vaccination and adverse reactions: guidance for clinicians", Morbidity and Mortality Weekly Report 52(RR-4): 1-29 (February 21, 2003) |
| | BK | Advisory Committee on Immunization Practices (ACIP), "Vaccinia (smallpox) vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR, 50(RR-10): 1-26 & ccl-ce7 (June 22, 2001) |
| | BL | Aebischer et al., "Long-Term Cross-Species Brain Transplantation of a Polymer-Encapsulated Dopamine-Secreting Cell Line," Experimental Neurology 111:269-275 (1991) |
| | BM | Aebischer et al., "Functional Recovery in Hemiparkinsonian Primates Transplanted with Polymer-Encapsulated PC12 Cells," Experimental Neurology 126:151-158 (1994) |
| | BN | Aguilar, O.M. et al., "The <i>nifEN</i> genes participating in FeMo cofactor biosynthesis and genes encoding dinitrogenase are part of the same operon in <i>Bradyrhizobium</i> species. Mol Gen Genet. 224(3):413-20 (1990) |
| | BO | Alcamí, A. et al., "Vaccinia virus strains Lister, USSR and Evans express soluble and cell-surface tumour necrosis factor receptors", J. Gen. Virol., 80: 949-959 (1999) |
| | BP | Antoine, G. et al., "Characterization of the vaccinia MVA hemagglutinin gene locus and its evaluation as an insertion site for foreign genes", Gene, 177: 43-46 (1996) |
| | BQ | Arakawa, S. et al., "Clinical trial of attenuated vaccinia virus AS strain in the treatment of advanced adeocarcinoma", J. Cancer Res. Clin. Oncol., 113: 95-98 (1987) |
| | BR | Baeksgaard, L. and J.B. Sorensen, "Acute tumor lyssi syndrome in solid tumors--a case report and review of the literature", Cancer Chemother. Pharmacol., 51: 187-192 (2003) |
| <i>MLK</i> | BS | Baker, R.O. et al., "Potential antiviral therapies for smallpox, monkeypox, and other orthopoxvirus infections", Antiviral Research, 57: 13-23 (2003) |

| | |
|---|---------------------------|
| Examiner Signature <i>Reed A. Kelly</i> | Date Considered 6/2/06 |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

| | | | | | |
|---|--------------|---|--|---------------------------------------|--|
| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | | Attorney's Docket No. 17248-004002 | Application No. 10/849,664 |
| List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | | | | Applicant Szalay, et al. | |
| | | | | Filing Date May 19, 2004 | Group Art Unit 1632 1633 |
| Other Documents (include Author, Title, Date, and Place of Publication) | | | | | |
| Examiner Initial | Desig. ID | Document | | | |
| <i>RK</i> | BT | Balkwill, F., "Chemokine biology in cancer", Seminars in Immunol., 15: 49-55 (2003) | | | |
| | BU | Baxby, D., "Poxviruses", Chapter 15 in <i>Principles and Practice of Clinical Virology</i> , Zuckerman, A.J. et al.(eds.), John Wiley & Sons Ltd., pp. 451-465 (2000) | | | |
| | BV | Beebe, J.L. and E.W. Koneman, "Recovery of Uncommon Bacteria from Blood: Association with Neoplastic Disease," Clin. Microbiol. Rev., 8(3): 336-356 (1995) | | | |
| | BW | Beerntsen, B.T. et al., "Genetics of Mosquito Vector Competenc," Microbiol. Mol. Biol. Rev., 64(1): 115-137 (2000) | | | |
| | BX | Belas et al., "Bacterial Bioluminescence: Isolation and Expression of the Luciferase Genes from <i>Vibrio harveyi</i> ," Science, 218: 791-793 (1982) | | | |
| | BY | Bell, J.C. et al., "Getting oncolytic virus therapies off the ground," Cancer Cell, 4: 7-11 (2003) | | | |
| | BZ | Bendig, M.M., "The production of foreign proteins in mammalian cells," Genetic Engineering 7:91-127 (1988) | | | |
| | CA | Bergsland, E.K. and A.P. Venook, "Shedding Old Paradigms: Developing Viruses to Treat Cancer," J. Clin. Oncol., 20(9): 2220-2222 (2002) | | | |
| | CB | Bermudes et al., "Live bacteria as anticancer agents and tumor-selective protein delivery vectors," Current Opinion in Drug Discovery & Development 5(2):194-199 (2002) | | | |
| | CC | Best et al., "Baboon/human homologies examined by spectral karyotyping (SKY): a visual comparison," Cytogenet Cell Genet. 82(1-2):83-7 (1998) | | | |
| | CD | Bickels, J. et al., "Coley's toxin: historical perspective", Isr. Med. Assoc. J., 4(6): 471-472 (2002) | | | |
| | CE | Blanchard, T.J. et al., "Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine," Journal of General Virology, 79: 1159-1167 (1998) | | | |
| | CF | Blasco, R. and B. Moss, "Selection of recombinant vaccinia viruses on the basis of plaque formation," Gene, 158: 157-162 (1995) | | | |
| | CG | Bogdahn et al., "Autocrine Tumor Cell Growth-inhibiting Activities from Human Malignant Melanoma", Cancer Research 49:5358-5363 (1989) | | | |
| | CH | Borellini, F. and J.M. Ostrove, "The Transfer of Technology from the Laboratory to the Clinic: In Process Controls and Final Product Testing", Chapter 18 in <i>Gene Therapy Technologies, Applications and Regulations</i> , A. Meager (Ed.), John Wiley & Sons Ltd., pp. 359-373 (1999) | | | |
| | CI | Boulanger, D. et al., "Morphogenesis and release of fowlpox virusm," Journal of General Virology, 81: 675-687 (2000) | | | |
| | CJ | Bouvier et al., "Functional characterization of the human dopamine D-4.2 receptor using vaccinia virus as an expression system," European Journal of Pharmacology 290(1):11-17 (1995) | | | |
| | CK | Boyd, J.E., "Facilities for Large-Scale Production of Vectors under GMP Conditions", Chapter 20 in <i>Gene Therapy Technologies, Applications and Regulations</i> , A. Meager (Ed.), pp. 383-400 (1999) | | | |
| | CL | Brain, J.D. et al., "Pulmonary intravascular macrophages: their contribution to the mononuclear phagocyte system in 13 species", Am. J. Physiol., 276(1 pt 1): L146-L154 (1999) | | | |
| | CM | Breman, J.G. and D.A. Henderson, "Diagnosis and Management of Smallpox", N. Engl. J. Med., 346(17): 1300-1308 (2002) | | | |
| <i>RK</i> | CN | Broder, C.C. et al., "Expression of foreign genes in cultured human primary macrophages using recombinant vaccinia virus vectors", Gene, 142: 167-174 (1994) | | | |
| Examiner Signature <i>R. A. Kelly</i> | | Date Considered 6/2/06 | | | |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | |

| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | | Attorney's Docket No. 17248-004002 | Application No. 10/849,664 |
|---|--------------|--|--|---------------------------------------|--|
| List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | | | | Applicant Szalay, et al. | |
| | | | | Filing Date May 19, 2004 | Group Art Unit 1632 1633 |
| Other Documents (include Author, Title, Date, and Place of Publication) | | | | | |
| Examiner Initial | Desig. ID | Document | | | |
| <i>mk</i> | CO | Broyles, S.S., "Vaccinia virus transcription", Journal of General Virology, 84: 2293-2303 (2003) | | | |
| | CP | Brunke M et al., "Luciferase assembly after transport into mammalian microsomes involves molecular chaperones and peptidyl-prolyl cis/trans-isomerases," J Biol Chem. 271(38):23487-94 (1996) | | | |
| | CQ | Carroll, S.F. and R.J. Collier, "Active Site of Pseudomonas aeruginosa Exotoxin A," J. Biol. Chem. 262:8707-8711 (1987) | | | |
| | CR | Carter, G.C. et al., "Vaccinia virus cores are transported on microtubules", Journal of General Virology, 84: 2443-2458 (2003) | | | |
| | CS | Cavanagh, L.L. and U.H. von Andrian, "Travellers in many guises: The origins and destinations of dendritic cells", Immunology and Cell Biology, 80: 448-462 (2002) | | | |
| | CT | Chalfie et al., "Green Fluorescent Protein as a Marker for Gene Expression," Science 263: 802-805 (1994) | | | |
| | CU | Chambers, A.F. et al., "Dissemination and Growth of Cancer Cells in Metastatic Sites," Nat. Rev. Cancer, 2: 563-572 (2002) | | | |
| | CV | Chambers, A.F. et al., "Molecular biology of breast cancer metastasis Clinical implications of experimental studies on metastatic inefficiency," Breast Cancer Res., 2: 400-407 (2000) | | | |
| | CW | Chaudhary et al., "Role of domain II of Pseudomonas exotoxin in the secretion of proteins into the periplasm and medium by Escherichia coli," Proc. Natl. Acad. Sci. USA 85: 2939-2943 (1988) | | | |
| | CX | Cheadle, E.J. and A.M. Jackson, "Bugs as Drugs for Cancer", Immunol., 107: 10-19 (2002) | | | |
| | DA | Chen et al. "Evaluation of combined vaccinia virus-mediated antitumor gene therapy with p53, IL-2, and IL-12 in a glioma model." Cancer Gene Ther. 7(11):1437-47 (2000) | | | |
| | DB | Chen et al. "Cancer gene therapy by direct tumor injections of a nonviral T7 vector encoding a thymidine kinase gene," Hum Gene Ther. 9(5):729-36 (1998) | | | |
| | DC | Chiocca, E.A., "Oncolytic Viruses", Nat. Rev. Cancer, 2(12): 938-950 (2002) | | | |
| | DD | Choi et al., "Efficient secretory production of alkaline phosphatase by high cell density culture of recombinant <i>Escherichia coli</i> using the <i>Bacillus</i> sp. endoxylanase signal sequence," Appl. Microbiol. Biotechnol. 53:640-645 (2000) | | | |
| | DE | Cichutek, K., "Development and Regulation of Gene Therapy Drugs in Germany", Chapter 17 in Gene Therapy Technologies, Applications and Regulations, A. Meager (Ed.), John Wiley & Sons Ltd. pp. 347-358 (c1999) | | | |
| | DF | Clairmont, C. et al., "Enhanced antitumor activity from tumor-targeting Salmonella expressing endostatin," American Association for Cancer Research: 91st Annual Meeting of the AACR, April 1-5, 2000, 41:732 Abstract #4653 (2000) | | | |
| | DG | Compton, J.L. and A.A. Szalay, "Insertion of nonhomologous DNA into the yeast genome mediated by homologous recombination with a cotransforming plasmid," Mol Gen Genet. 188(1):44-50 (1982) | | | |
| | DH | Condeelis, J. and J.E. Segall, "Intravital imaging of cell movement in tumours", Nat. Rev. Cancer, 3: 921-930 (2003) | | | |
| <i>mk</i> | DI | Contag et al., "Photonic detection of bacterial pathogens in living hosts," Mol. Microbiol. 18: 593-603 (1995) | | | |

| | |
|---|----------------------------------|
| Examiner Signature <i>R. I. Kelly</i> | Date Considered <i>6/2/06</i> |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

| | | | | |
|---|--------------|--|---------------------------------------|-------------------------------|
| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 17248-004002 | Application No. 10/849,664 |
| List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | | | Applicant Szalay, et al. | |
| | | | Filing Date May 19, 2004 | Group Art Unit 1632/633 |
| Other Documents (include Author, Title, Date, and Place of Publication) | | | | |
| Examiner Initial | Desig. ID | Document | | |
| <i>PK</i> | DJ | Coupar, B.E.H. et al., "A general method for the construction of recombinant vaccinia viruses expressing multiple foreign genes", Gene, 68: 1-10 (1988) | | |
| | DK | Coussens, L.M. and Z. Werb, "Inflammation and cancer", Nature, 420: 860-867 (2002) | | |
| | DL | Craperi et al. "Increased bax expression is associated with cell death induced by ganciclovir in a herpes thymidine kinase gene-expressing glioma cell line." Hum Gene Ther. 10(4):679-688 (1999) | | |
| | DM | Cseh, S. et al., "Rapid freezing of mouse embryos in ethylene glycol at different preimplantation stages," Acta Veterinaria Hungarica 44(4):457-65 (1996) | | |
| | DN | Culver et al., "In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors." Science. 256(5063):1550-2 (1992) | | |
| | DO | Davis, C. et al., "The role of inflammation in vascular injury and repair", Journal of Thrombosis and Haemostasis, 1: 1699-1709 (2003) | | |
| | DP | De Clercq, E., "Cidofovir in the therapy and short-term prophylaxis of poxvirus infections", Trends in Pharmacological Sciences, 23(10): 456-458 (2002) | | |
| | DQ | Demers, G.W. et al., "Pharmacologic Indicators of Antitumor Efficacy for Oncolytic Virotherapy", Cancer Res., 63: 4003-4008 (2003) | | |
| | DR | Derwent English abstract for WO 94/10302, published May 11, 1994 entitled: "Vectors inhibiting HIV replication in potential host cells - contg. DNA encoding Pol, Gag, Env, Rev, and/or Tat in antisense direction and further DNA causing spontaneous amplification," Accession Nbr. 1994-152544 [19] | | |
| | DS | de Wet et al., "Firefly Luciferase Gene: Structure and Expression in Mammalian Cells," Mol. Cell. Biol. 7: 725-737 (1987) | | |
| | DT | Diamond, D.C. ET AL. "Sequence comparison of baboon ABO histo-blood group alleles: lesions found in O alleles differ between human and baboon," Blood Cells Mol Dis. 23(2):242-51 (1997) | | |
| | DU | Diamond, D.C., et al., "Genotyping the baboon ABO histo-blood group locus by two-color fluorescence SSCP," Biotechniques 27(5):1054, 1056, 1058-59, 1061 (1999) | | |
| | DV | Dietrich, G. et al., "Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attenuated suicide <i>Listeria monocytogenes</i> ," Nat Biotechnol. 16(2):181-5 (1998) | | |
| | DW | Ding et al., "Zinc-dependent dimers observed in crystals of human endostatin," Proc. Natl. Acad. Sci. USA 95:10443-10448 (1998) | | |
| | DX | Dobbelstein, M., "Viruses in therapy-- royal road or dead end?", Virus Research, 92: 219-221 (2003) | | |
| | DY | Domi, A. and B. Moss, "Cloning the vaccinia virus genome as a bacterial artificial chromosome in Escherichia coli and recovery of infectious virus in mammalian cells", Proc. Natl. Acad. Sci. U.S.A., 99(19): 12415-12420 (2002) | | |
| | DZ | Dull et al., "Insulin-like growth factor II precursor gene organization in relation to insulin gene therapy," Nature 310: 777-781 (1984) | | |
| | EA | Eastham et al. "Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models." Hum Gene Ther. 7(4):515-23 (1996) | | |
| | EB | Ehrensgruber, M.U., "Alphaviral gene transfer in neurobiology", Brain Research Bulletin, 59(1): 13-22 (2002) | | |
| <i>PK</i> | EC | Engbrecht et al., "Measuring Gene Expression with Light," Science 227: 1345-1347 (1985) | | |
| Examiner Signature <i>Robert A. Kelly</i> | | Date Considered 6/2/06 | | |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | |

| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 17248-004002 | Application No. 10/849,664 |
|---|--------------|--|---------------------------------------|-------------------------------|
| List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | | | Applicant Szalay, et al. | |
| | | | Filing Date May 19, 2004 | Group Art Unit 1632 / 633 |
| Other Documents (include Author, Title, Date, and Place of Publication) | | | | |
| Examiner Initial | Desig. ID | Document | | |
| RUK | EA | Escher, A. et al., "Bacterial luciferase $\alpha\beta$ fusion protein is fully active as a monomer and highly sensitive <i>in vivo</i> to elevated temperature," <i>Proc Natl Acad Sci U S A.</i> 86(17):6528-32 (1989) | | |
| | EB | Escher, A et al., "The β subunit polypeptide of <i>Vibrio harveyi</i> luciferase determines light emission at 42° C," <i>Mol Gen Genet.</i> 230(3):385-93 (1991) | | |
| | EC | Escher, A. and A.A. Szalay, "GroE-mediated folding of bacterial luciferases <i>in vivo</i> ," <i>Mol Gen Genet.</i> 238(1-2):65-73 (1993) | | |
| | ED | Esposito, J.J. and F. Fenner, "Poxviruses", Chapter 85 in <i>Field's Virology</i> , 4th Edn., vol. 2, pp. 2885-2921. Edited by D. M. Knipe and P. M. Howley, Philadelphia: Lippincott Williams & Wilkins, (2001) | | |
| | EE | Fatyol, K et al., "Mer22-related sequence elements form pericentric repetitive DNA families in primates," <i>Mol Gen Genet.</i> 262(6):931-9 (2000) | | |
| | EF | Fatyol, K et al. "Molecular characterization of a stably transformed <i>Bombyx mori</i> cell line: identification of alternative transcriptional initiation sites of the A3 cytoplasmic actin gene." <i>Mol Gen Genet.</i> 260(1):1-8 (1998) | | |
| | EG | Fatyol, K et al., "An alternative intronic promoter of the <i>Bombyx</i> A3 cytoplasmic actin gene exhibits a high level of transcriptional activity in mammalian cells," <i>Mol Gen Genet.</i> 261(2):337-45 (1999) | | |
| | EH | Fatyol, K and A.A. Szalay, "The p14 ^{ARF} tumor suppressor protein facilitates nucleolar sequestration of hypoxia-inducible factor-1 α (HIF-1 α) and inhibits HIF-1-mediated transcription," <i>J Biol Chem.</i> 276(30):28421-28429 (2001) | | |
| | EI | Fernández-Piñas, F. and C.P. Wolk, "Expression of <i>luxCD-E</i> in <i>Anabaena</i> sp. can replace the use of exogenous aldehyde for <i>in vivo</i> localization of transcription by <i>luxAB</i> ," <i>Gene</i> 150:169-174 (1994) | | |
| | EJ | Fidler, I.J., "The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited", <i>Nature Cancer Research</i> , 3: 1-6 (2003) | | |
| | EK | Foran, D.R. and W.M. Brown, "Nucleotide sequence of the <i>LuxA</i> and <i>LuxB</i> genes of the bioluminescent marine bacterium <i>Vibrio fischeri</i> ," <i>Nucleic Acids Res.</i> 16: 777 (1988) | | |
| | EL | Forbes, N.S. et al., "Sparse Initial Entrapment of Systematically Injected <i>Salmonella typhimurium</i> Leads to Heterogenous Accumulation within Tumors," <i>Cancer Res.</i> , 63: 5188-5193 (2003) | | |
| | EM | Fox, A.W., "Emergency and Compassionate-use INDs and Accelerated NDS or ANDA Approvals--Procedures, Benefits and Pitfalls", Chapter 26 in <i>Principles and Practice of Pharmaceutical Medicine</i> , A.J. Fletcher, et al.(Eds.), John Wiley & Sons, pp.299-305, (2002) | | |
| | EN | Freed et al., "Survival of Implanted Fetal Dopamine Cells and Neurologic Improvement 12 to 46 Months After Transplantation for Parkinson's Disease," <i>New England Journal of Medicine</i> 327:1549-1555 (1992) | | |
| | EO | Freitag, N.E. and K.E. Jacobs, "Examination of <i>Listeria monocytogenes</i> Intracellular Gene Expression by Using Green Fluorescent Protein of <i>Aequorea victoria</i> ," <i>Infect.Immun.</i> 67:1844-1852 (1999) | | |
| | EP | Friberg, S. and S. Mattson, "On the Growth Rates of Human Malignant Tumors: Implications for Medical Decision Making," <i>Journal of Surgical Oncology</i> , 65: 284-297 (1997) | | |
| | EQ | Gallagher, R., "Vaccination Undermined", <i>The Scientist</i> , 17(22): 1-3 (2003) | | |
| RUK | ER | Geng, J.G., "Directional migration of leukocytes: their pathological roles in inflammation and strategies for development of anti-inflammatory therapies", <i>Cell Res.</i> , 11(2): 85-88 (2001) | | |

Examiner Signature

Robert A. Kelly

Date Considered


6/2/06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


| | | | | | |
|---|--------------|---|--|---------------------------------------|-------------------------------|
| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | | Attorney's Docket No. 17248-004002 | Application No. 10/849,664 |
| List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | | | | Applicant Szalay, et al. | |
| | | | | Filing Date May 19, 2004 | Group Art Unit +632 1633 |
| Other Documents (include Author, Title, Date, and Place of Publication) | | | | | |
| Examiner Initial | Desig. ID | Document | | | |
| TK | ES | Geng, J.G., "Interaction of vascular endothelial cells with leukocytes, platelets and cancer cells in inflammation, thrombosis and cancer growth and metastasis," Acta Pharmacol. Sin, 24(12): 1297-1300 (2003) | | | |
| | ET | Giacomin, L.T. and A.A. Szalay, "Expression of a PALI promoter luciferase gene function in Arabidopsis thaliana in response to infection by phytopathogenic bacteria," Plant Sci. 116: 59-72 (1996) | | | |
| | EU | Gnant, M.F.X. et al, "Tumor-Specific Gene Delivery Using Recombinant Vaccinia Virus in a Rabbit Model of Liver Metastases", Journal of the National Cancer Institute, 91(20): 1744-1750 (1999) | | | |
| | EV | Goetz et al., "Multicenter Study of Autologous Adrenal Medullary Transplantation to the Corpus Striatum in Patients with Advanced Parkinson's Disease", N. Eng. J. Med. 320:337-341 (1989) | | | |
| | EW | Goetz, M et al., "Microinjection and growth of bacteria in the cytosol of mammalian host cells," Proc Natl Acad Sci U S A. 98(21):12221-12226. (2001) | | | |
| | EX | Gomella, L.G. et al., "Phase I Study Of Intravesical Vaccinia Virus As A Vector For Gene Therapy Of Bladder Cancer", J. Urology, 166: 1291-1295 (2001) | | | |
| | EY | Gómez, C.E. and M. Esteban, "Recombinant proteins produced by vaccinia virus vectors can be incorporated within the virion (IMV form) into different compartments," Arch. Virol., 146: 875-892 (2001) | | | |
| | EZ | Graff, C.P. and K.D. Wittup, "Theoretical Analysis of Antibody Targeting of Tumor Spheroids: Importance of Dosage for Penetration, and Affinity for Retention", Cancer Res., 63: 1288-1296 (2003) | | | |
| | FA | Gray, J.W., "Evidence emerges for early metastasis and parallel evolution of primary and metastatic tumors", Cancer Cell, 4(1): 4-6 (2003) | | | |
| | FB | Green, D.R. and G.I. Evan, "A matter of life and death", Cancer Cell, 1: 19-30 (2002) | | | |
| | FC | Greer III, L.F. and A.A. Szalay, "Imaging of light emission from the expression of luciferases in living cells and organisms: a review," Luminescence. 17(1):43-74 (2002) | | | |
| | FD | Griffin, D.E., "A Review of Alphavirus Replication in Neurons", Neuroscience and Biobehavioral Reviews, 22(6): 721-723 (1998) | | | |
| | FE | Guy et al., "Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease," Proc. Natl. Acad. Sci. USA 89: 10578-10582 (1992) | | | |
| | FF | Grove et al. "Virus-directed enzyme prodrug therapy using CB1954" Anti-Cancer Drug Design 14(6) 461-472 (1999) | | | |
| | FG | Hacein-Bey-Abina, S. et al., "A Serious Adverse Event after Successful Gene Therapy for X-Linked Severe Combined Immunodeficiency", N. Engl. J. Med., 348(3): 255-266 (2003) | | | |
| | FH | Hadley, R.G. et al., "Conservation of DNA regions adjacent to nifKDH homologous sequences in diverse slow-growing Rhizobium strains," J Mol Appl Genet. 2(3):225-36 (1983) | | | |
| | FI | Haghighat et al. "Antitumor effect of IL-2, p53, and bax gene transfer in C6 glioma cells," Anticancer Res. 20(3A):1337-42 (2000) | | | |
| | FJ | Hall et al., "Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer," Int J Cancer. 70(2):183-7 (1997) | | | |
| TK | FK | Halsell, J.S. et al., "Myopericarditis Following Smallpox Vaccination Among Vaccinia-Naïve US Military Personnel", J. Am. Med. Assoc., 289(24): 3283-3289 (2003) | | | |
| Examiner Signature | | Date Considered | | | |
| [Signature] | | 6/2/06 | | | |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | |

| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 17248-004002 | Application No. 10/849,664 |
|---|--|--|---------------------------------------|--|
| List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | | | Applicant Szalay, et al. | |
| | | | Filing Date May 19, 2004 | Group Art Unit 1632 1633 |
| Other Documents (include Author, Title, Date, and Place of Publication) | | | | |
| Examiner Initial | Desig. ID | Document | | |
| ZMK | FL | Hanahan, D. and R.A. Weinberg, "The Hallmarks of Cancer", Cell, 100: 57-70 (2000) | | |
| | FM | Hansen, R.M. and J.A. Libnoch, "Remission of Chronic Lymphocytic Leukemia After Smallpox Vaccination", Arch. Intern. Med., 138: 1137-1138 (1978) | | |
| | FN | Hawkins, L.K. et al., "Oncolytic biotherapy: a novel therapeutic platform", The Lancet Oncology, 3: 17-26 (2002) | | |
| | FO | Hemann et al., "High-Copy Expression Vector Based on Amplification-Promoting Sequences", DNA and Cell Biology 13:437-445 (1994) | | |
| | FP | Hermiston, T.W. and I. Kuhn, "Armed therapeutic viruses: Strategies and challenges to arming oncolytic viruses with therapeutic genes", Cancer Gene Therapy, 9: 1022-1035 (2002) | | |
| | FQ | Hershey, P. et al., "Adjuvant Immunotherapy of Patients With High-Risk Melanoma Using Vaccinia Viral Lysates of Melanoma: Results of a Randomized Trial", Journal of Clinical Oncology, 20(20): 4181-4190 (2002) | | |
| | FR | Hess et al., "Listeria monocytogenes p60 supports host cell invasion by and in vivo survival of attenuated Salmonella typhimurium," Infect Immun. 63(5):2047-53 (1995) | | |
| | FS | Hollinshead, M. et al., "Vaccinia virus utilizes microtubules for movement to the cell surface," Journal of Cell Biology, 154: 389-402 (2001) | | |
| | FT | Holló, G et al., "Evidence for a megareplicon covering megabases of centromeric chromosome Segments," Chromosome Res. 4(3):240-7 (1996) | | |
| | FU | Hosokawa et al., "Pituitary Carcinoma of Pars Distalis as a Common Neoplasm in Fischer-344 Rats," Toxicol. Pathol. 21: 283-287 (1993) | | |
| | FV | Hughes, R.G. and N. Turner, "Financial Aspects of Clinical Trials", Chapter 42 in Principles and Practice of Pharmaceutical Medicine, A.J. Fletcher, et al.(eds.), pp. 501-512, John Wiley & Sons, Ltd. (2002) | | |
| | FW | Humlova, Z. et al., "Vaccinia virus induces apoptosis of infected macrophages," J. General Virol., 83: 2821-2832 (2002) | | |
| | FX | Jain, R.K. and B.T. Fenton, "Intratumoral Lymphatic Vessels: A Case of Mistaken Identity or Malfunction?", Journal of the National Cancer Institute, 94(6): 417-421 (2002) | | |
| | FY | Jain, R.K., "Molecular regulation of vessel maturation", Nat. Med., 9(6): 685-693 (2003) | | |
| | FZ | Jemal, A. et al., "Cancer Statistics, 2003", CA Cancer J Clin, 53(1): 5-26 (2003) | | |
| | GA | Jeong, K.J. and S.Y. Lee, "Secretory Production of Human Leptin in Escherichia coli," Biotechnol. Bioeng. 67:398-407 (2000) | | |
| | GB | Kaniga et al., "Homologs of the Shigella IpaB and IpaC Invasins are Required for Salmonella typhimurium Entry into Cultured Epithelial Cells," J. Bacteriol. 177: 3965-3971 (1995) | | |
| | GC | Kawa, A. and S. Arakawa, "The Effect of Attenuated Vaccinia Virus AS Strain on Multiple Myeloma; A Case Report", Japan. J. Exp. Med. 58(1): 79-81 (1987) | | |
| | GD | Keith, K.A. et al., "Evaluation of Nucleoside Phosphonates and Their Analogs and Prodrugs for Inhibition of Orthopoxvirus Replication," Antimicrob. Agents Chemother., 47(7): 2193-2198 (2003) | | |
| GE | Keresó, J. et al., "De novo chromosome formations by large-scale amplification of the centromeric region of mouse chromosomes," Chromosome Res. 4(3):226-39 (1996) | | | |
| GF | Kern, E.R., "In vitro activity of potential anti-poxvirus agents", Antiviral Research 57: 35-40 (2003) | | | |

Examiner Signature




Date Considered




EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| Substitute Form, PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 17248-004002 | Application No. 10/849,664 |
|---|--------------|--|---------------------------------------|-------------------------------|
| List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | | | Applicant Szalay, et al. | |
| | | | Filing Date May 19, 2004 | Group Art Unit 1632 / 633 |
| Other Documents (include Author, Title, Date, and Place of Publication) | | | | |
| Examiner Initial | Desig. ID | Document | | |
| TUK | GG | Kihara, A. and I. Pastan, "Analysis of Sequences Required for the Cytotoxic Action of a Chimeric Toxin Composed of Pseudomonas Exotoxin and Transforming Growth Factor α ," Bioconj.Chem. 5: 532-538 (1994) | | |
| | GH | Kim, E.M. et al., "Overview analysis of adjuvant therapies for melanoma: a special reference to results from vaccinia melanoma oncolysate adjuvant therapy trials", Surgical Oncology, 10: 53-59 (2001) | | |
| | GI | Kleer, C.G. et al., "Molecular biology of breast cancer metastasis: Inflammatory breast cancer: clinical syndrome and molecular determinants," Breast Cancer Res. 2: 423-429 (2000) | | |
| | GJ | Kneissl, M. et al., "Interaction and assembly of murine pre-replicative complex proteins in yeast and mouse cells," J Mol Biol. 327(1):111-28 (2003) | | |
| | GK | Kolowsky K.S. et al., "Length of foreign DNA in chimeric plasmids determines the efficiency of its integration into the chromosome of the cyanobacterium Synechococcus R2," Gene 27(3):289-99 (1984) | | |
| | GL | Kondo et al., "Activity of Immunotoxins Constructed with Modified Pseudomonas Exotoxin A Lacking the Cell Recognition Domain," J.Biol.Chem. 263: 9470-9475 (1988) | | |
| | GM | Krauss, O. et al., "An investigation of incorporation of cellular antigens into vaccinia virus particles", Journal of General Virology, 83: 2347-2359 (2002) | | |
| | GN | Kruse, M. et al., "Enzyme assembly after de novo synthesis in rabbit reticulocyte lysate involves molecular chaperones and immunophilins," J Biol Chem. 270(6):2588-94 (1995) | | |
| | GO | Kubes, P., "Introduction: The complexities of leukocyte recruitment", Seminars in Immunol., 14: 65-72 (2002) | | |
| | GP | Kunkel, E.J. and E.C. Butcher, "Plasma-cell homing", Nature Reviews Immunology, 3: 822-829 (2003) | | |
| | GQ | Kwak, H. et al., "Poxviruses as vectors for cancer immunotherapy", Curr. Opin. Drug Disc. Develop., 6(2): 161-168 (2003) | | |
| | GR | Langridge W.H. et al., "Detection of baculovirus gene expression in insect cells and larvae by low light video image analysis," J Virol Methods. 61(1-2):151-6 (1996) | | |
| | GS | Langridge W.H. et al., "Uptake of DNA and RNA into cells mediated by electroporation," Methods Enzymol. 153:336-50. (1987) | | |
| | GT | Langridge, W.H. and , A.A.Szalay, "Bacterial and coelenterate luciferases as reporter genes in plant cells," Chapter 37 in Methods Mol Biol. 82:385-96.(1998) | | |
| | GU | Larson et al. "Triumph over mischance: a role for nuclear medicine in gene therapy," J Nucl Med. 38(8):1230-3 (1997) | | |
| | GV | Lawrence J.C., "The bacteriology of burns", J. of Hospital Infection 6: 3-17 (1985) | | |
| | GW | Lee et al., "The lux genes of the luminous bacterial symbiont <i>Photobacterium leiognathi</i> , of the ponyfish," Eur. J. Biochem. 201: 161-167 (1991) | | |
| | GX | Legocki et al., "Bioluminescence in soybean root nodules: Demonstration of a general approach to assay gene expression <i>in vivo</i> by using bacterial luciferase," Proc. Natl. Acad. Sci 83: 9080-9084 (1986) | | |
| TUK | GY | Ley, K., "Integration of inflammatory signals by rolling neutrophils", Immunological Reviews, 186: 8-18 (2002) | | |

| | | | |
|---|---|-----------------|--------|
| Examiner Signature |  | Date Considered | 6/2/06 |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | |

| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 17248-004002 | Application No. 10/849,664 |
|---|--------------|--|---------------------------------------|-------------------------------|
| List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | | | Applicant Szalay, et al. | |
| | | | Filing Date May 19, 2004 | Group Art Unit 1632 1633 |
| Other Documents (include Author, Title, Date, and Place of Publication) | | | | |
| Examiner Initial | Desig. ID | Document | | |
| RMK | GZ | Ley, K., "The role of selectins in inflammation and disease", Trends in Molec. Med., 9(6): 263-268 (2003) | | |
| | HA | Li et al "An engineered and assembled fusion protein of antitumor antibiotic lidamycin and scFV antibody directed against type IV collagenase" Yaouxue Xuebao 35(7) 488-91 (July, 2000) [English abstract on last page of article] | | |
| | HB | Lindvall et al., "Grafts of Fetal Dopamine Neurons Survive and Improve Motor Function in Parkinson's Disease," Science 237:574-577 (1990) | | |
| | HC | Liu, H et al., "Detection of GDNF secretion in glial cell culture and from transformed cell implants in the brains of live animals," Mol Genet Genomics. 266(4):614-23. (2001) | | |
| | HD | Liu, J. et al., "Visualizing and quantifying protein secretion using a Renilla luciferase-GFP fusion protein," Luminescence. 15(1):45-49 (2000) | | |
| | HE | Lorenz et al., "Isolation and expression of a cDNA encoding <i>Renilla reniformis</i> luciferase," PNAS USA 88: 4438-4442 (1991) | | |
| | HF | Lorenz et al., "Expression of the Renilla reniformis luciferase gene in mammalian cells," J Biolumin Chemilumin. 11(1):31-7 (1996) | | |
| | HG | Louie, A.Y. et al., "In vivo visualization of gene expression using magnetic resonance imaging", Nature Biotechnology, 18: 321-325 (2000) | | |
| | HH | Luscinskas, F.W. et al., "Leukocyte transendothelial migration: A junctional affair", Seminars in Immunology, 14: 105-113 (2002) | | |
| | HI | Luscinskas, F.W. et al., "The role of endothelial cell lateral junctions during leukocyte trafficking", Immunological Reviews, 186: 57-67 (2002) | | |
| | HJ | Lusso, P., "Chemokines and Viruses: The Dearest Enemies", Virology, 273: 228-240 (2000) | | |
| | HK | Lyford, J., "Gene therapy 'cause T-cell leukemia': Insertional mutagenesis pinpointed as cause of T-cell Leukemia in X-SCID gene therapy trial", The Scientist, (Daily News, October 20, 2003) pgs. 1-4 (2003) | | |
| | HL | MacDonald, I.C. et al., "Cancer spread and micrometastasis development: quantitative approaches for in vivo models", BioEssays, 24: 885-893 (2002) | | |
| | HM | MacLaren et al. "Receptive non-invasive imaging of the dopamine D2 receptor gene in living animals" Gene Therapy (MacMillan Press)v.6 pp785-791, May (1995) | | |
| | HN | MacLeod R.A. et al., "Expression of genes from the marine bacterium <i>Alteromonas haloplanktis</i> 214 in <i>Escherichia coli</i> K-12," Arch Microbiol. 142(3):248-52 (1985) | | |
| | HO | Maeda, H. et al., "Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review", J. Controlled Release, 65: 271-284 (2000) | | |
| | HP | Mahy, B.W.J., "An overview on the use of a viral pathogen as a bioterrorism agent: why smallpox?", Antivir. Res., 57: 1-5 (2003) | | |
| | HQ | Maina C.V. et al., "Molecular weight determination program," Nucleic Acids Res. 12(1 Pt 2):695-702 (1984) | | |
| ✓ | HR | Makower, D. et al., "Phase II Clinical Trial of Intravesical Administration of the Oncolytic Adenovirus ONYX-015 in Patients with Hepatobiliary Tumors with Correlative p53 Studies," Clin. Cancer Res., 9: 693-702 (2003) | | |
| RMK | HS | Mastrangelo, M.J. et al., "Poxvirus vectors: orphaned and underappreciated", J. Clin. Invest., 105(8): 1031-1034 (2000) | | |

| | |
|---|---------------------------|
| Examiner Signature  | Date Considered 6/2/06 |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |


| | | | | |
|---|--------------|---|---------------------------------------|-------------------------------|
| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 17248-004002 | Application No. 10/849,664 |
| List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | | | Applicant Szalay, et al. | |
| | | | Filing Date May 19, 2004 | Group Art Unit 1632 1633 |
| Other Documents (include Author, Title, Date, and Place of Publication) | | | | |
| Examiner Initial | Desig. ID | Document | | |
| MK | HT | Matz et al., "Fluorescent proteins from nonbioluminescent Anthozoa species," Nat. Biotech. 17: 969-973 (1999) | | |
| | HU | Mayerhofer, R et al., "Monitoring of spatial expression of firefly luciferase in transformed zebrafish," J Biolumin Chemilumin. 10(5):271-5 (1995) | | |
| | HV | McCart, J.A. et al., "Complex interaction between the replicating oncolytic effect and the enzyme/prodrug effect of vaccinia-mediated tumor regression", Gene Therapy, 7: 1217-1223 (2000) | | |
| | HW | McCart, J.A. et al., "Systemic Cancer Therapy with a Tumor-selective Vaccinia Virus Mutant Lacking Thymidine Kinase and Vaccinia Growth Factor Genes", Cancer Research, 61: 8751-8757 (2001) | | |
| | HX | McDonald, D.M. and P.L. Choyke, "Imaging of angiogenesis: from microscope to clinic", Nature Medicine, 9(6): 713-725 (2003) | | |
| | HY | Meager, A. et al., "The Development of the Regulatory Process in Europe for Biological Medicines: How it Affects Gene Therapy Products", Chapter 16 in <i>Gene Therapy Technologies, Applications and Regulations</i> , A. Meager (Ed.), John Wiley & Sons Ltd., pp. 319-346 (1999) | | |
| | HZ | Meighen, E.A. and R.B. Szittner, "Multiple Repetitive Elements and Organization of the lux Operons of Luminescent Terrestrial Bacteria," J. Bacteriol. 174(16):5371-5381 (1992) | | |
| | IA | Mengaud et al., "Expression in <i>Escherichia coli</i> and Sequence Analysis of the Listeriolysin O Determinant of <i>Listeria monocytogenes</i> ," Infect. Immun. 56(4): 766-772 (1988) | | |
| | IB | Middleton, J. et al., "Leukocyte extravasation: chemokine transport and presentation by the endothelium", Blood, 100(12): 3853-3860 (2002) | | |
| | IC | Moore et al., "Measuring transferrin receptor gene expression by NMR imaging," Biochimica et Biophysica Acta 1402(3):239-249 (1998) | | |
| | ID | Moore, A.E., "Effects of Viruses on Tumors", Annu. Rev. Microbiol., 8: 393-402 (1954) | | |
| | IE | Moretta, A., "Natural Killer Cells and Dendritic Cells: Rendezvous in Abused Tissues", Nat. Rev. Immunol., 2: 957-964 (2002) | | |
| | IF | Morris, D.W. et al., "Plasmid vectors capable of transferring large DNA fragments to yeast," DNA. 1(1):27-36 (1981) | | |
| | IG | Moss, B., "Poxviridae: the viruses and their replication," Chapter 84 in Field's Virology, 4 th Edn., vol. 2, pp. 2849-2883. Edited by D. M. Knipe and P. M. Howley, Philadelphia: Lippincott Williams & Wilkins, (2001) | | |
| | IH | Moss, B., "Poxviridae: the viruses and their replication," Chapter 83 in Fields Virology, 3rd Edn, pp. 2637-2671. Edited by B. N. Fields, D. M. Knipe & P. M. Howley. Philadelphia: Lippincott-Raven (1996) | | |
| | II | Mountz et al. "Technetium-99m NeoTect imaging <i>in vivo</i> of T cells from hCAR transgenic mice," FASEB J. 16(5):A1211 March Meeting abstract (2002) | | |
| | IJ | Nagahari et al. "Secretion into the culture medium of a foreign gene product from <i>Escherichia coli</i> : use of the <i>ompF</i> gene for secretion of human β -endorphin." EMBO J. 4(13A):3589-92 (1985) | | |
| | IK | Nettleton, P.F. et al., "Parapoxviruses are strongly inhibited <i>in vitro</i> by cidofovir," Antivir. Res., 48: 205-208 (2000) | | |
| MK | IL | Newton et al. "Expression and characterization of recombinant human eosinophil-derived neurotoxin and eosinophil-derived neurotoxin-anti-transferrin receptor sFv," J. Biol. Chem. 269(43):26739-45, (1994) | | |

Examiner Signature

Date Considered

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | | Attorney's Docket No. 17248-004002 | Application No. 10/849,664 |
|---|--------------|---|--|---------------------------------------|--|
| List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | | | | Applicant Szalay, et al. | |
| | | | | Filing Date May 19, 2004 | Group Art Unit 1632 1633 |
| Other Documents (include Author, Title, Date, and Place of Publication) | | | | | |
| Examiner Initial | Desig. ID | Document | | | |
| MK | IM | Neyts et al., "Therapy and short-term prophylaxis of poxvirus infections: historical background and perspectives", <i>Antivir. Res.</i> 57: 25-33 (2003) | | | |
| | IN | Nibbering et al. "Radiolabelled antimicrobial peptides for imaging of infections: a review," <i>Nucl Med Commun.</i> 19(12):1117-21 (1998) | | | |
| | IO | Nichterlein et al., "Clinafloxacin (CI 960) is Superior to Standard Therapeutics in the Treatment of Murine Listeriosis and Salmonellosis," <i>Zentralbl.Bakteriol.</i> 286: 401-412 (1997) | | | |
| | IP | Nisato, R.E. et al., "Lymphangiogenesis and tumor metastasis", <i>Thromb. Haemost.</i> , 90: 591-597 (2003) | | | |
| | IQ | Nolan G.P., et al., "Plasmid mapping computer program," <i>Nucleic Acids Res.</i> 12(1 Pt 2):717-29 (1984) | | | |
| | IR | Noti J.D. et al., "Organization and characterization of genes essential for symbiotic nitrogen fixation from <i>Bradyrhizobium japonicum</i> I110," <i>J Bacteriol.</i> 167(3):774-83 (1986) | | | |
| | IS | Noti J.D. et al., "Site-directed Tn5 and transplacement mutagenesis: methods to identify symbiotic nitrogen fixation genes in slow-growing <i>Rhizobium</i> ," <i>Methods Enzymol.</i> 154:197-217 (1987) | | | |
| | IT | Ober, B.T. et al., "Immunogenicity and Safety of Defective Vaccinia Virus Lister: Comparison with Modified Vaccinia Virus Ankara", <i>J. Virol.</i> , 76(15): 7713-7723 (2002) | | | |
| | IU | O'Kane et al., "Visualization of Bioluminescence as a Marker of Gene Expression in <i>Rhizobium</i> -Infected Soybean Root Nodules," <i>J. Plant Mol. Biol.</i> 10: 387-399 (1988). | | | |
| | IV | Olsson et al., "Engineering of monomeric bacterial luciferases by fusion of luxA and luxB genes in <i>Vibrio harveyi</i> ," <i>Gene</i> 81(2):335-47 (1989) | | | |
| | IW | Olsson, O. et al., "The use of the luxA gene of the bacterial luciferase operon as a reporter gene," <i>Mol Gen Genet.</i> 215(1):1-9 (1988) | | | |
| | IX | Overholser et al., "Experimental Bacterial Endocarditis after Dental Extractions in Rats with Periodontitis," <i>J. Infect. Dis.</i> 155(1) (1987), 107-112 | | | |
| | IY | Padera, T.P. et al., "Lymphatic Metastasis in the Absence of Functional Intratumor Lymphatics", 296: 1883-1886 (2002) | | | |
| | IZ | Paniacchi, D. et al., "Vaccinia virus vectors utilizing the β -galactosidase assay for rapid selection of recombinant viruses and measurement of gene expression", <i>Gene</i> , 47: 193-199 (1986) | | | |
| | JA | Pardal, R. et al., "Applying the principles of stem-cell biology to cancer," <i>Nature Reviews Cancer</i> , 3: 895-902 (2003) | | | |
| | JB | Parish, C.R., "Cancer immunotherapy: The past, the present and the future", <i>Immunology and Cell Biology</i> , 81: 106-113 (2003) | | | |
| | JC | Pawelek, J.M. et al., "Bacteria as tumour-targeting vectors," <i>The Lancet Oncology</i> , 4: 548-556 (2003) | | | |
| | JD | Pecora, A.L. et al., "Phase I Trial of Intravenous Administration of PV701, an Oncolytic Virus, in Patients With Advanced Solid Cancers", <i>Journal of Clinical Oncology</i> , 20(9): 2251-2266 (2002) | | | |
| | JE | Peplinski, G.R. et al., "Vaccinia Virus For Human Gene Therapy", <i>Surgical Oncology Clinics of North America</i> , 7(3): 575-588 (1998) | | | |
| | JF | Pluen, A. et al., "Role of tumor-host interactions in interstitial diffusion of macromolecules: Cranial vs. subcutaneous tumors", <i>Proc. Natl. Acad. Sci. U.S.A.</i> , 98(8): 4628-4633 (2001) | | | |
| MK | JG | Polverini et al., "Assay and Purification of Naturally Occuring Inhibitor of Angiogenesis," <i>Methods in Enzymology</i> 198:440-450 (1991) | | | |

| | |
|---|---------------------------|
| Examiner Signature  | Date Considered 6/2/06 |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |


| | | | | | |
|---|--------------|--|-------------------------------|---------------------------------------|--|
| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | | Attorney's Docket No. 17248-004002 | Application No. 10/849,664 |
| List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | | | | Applicant Szalay, et al. | |
| | | | | Filing Date May 19, 2004 | Group Art Unit 1632 1633 |
| Other Documents (include Author, Title, Date, and Place of Publication) | | | | | |
| Examiner Initial | Desig. ID | Document | | | |
| <i>MK</i> | JH | Pongor S. et al., "Microcomputer programs for prediction and comparative evaluation of protein secondary structure from nucleotide sequence data: application to ribulose-1,5-bisphosphate carboxylase sequences," DNA. 4(4):319-26 (1985) | | | |
| | JI | Pongor S. and A.A. Szalay, "Prediction of homology and divergence in the secondary structure of Polypeptides," Proc Natl Acad Sci U S A. 82(2):366-70 (1985) | | | |
| | JJ | Prasher et al., "Sequence Comparison of Complementary DNAs Encoding Aequorin Isotypes," Biochemistry 26: 1326-1332 (1987) | | | |
| | JK | Prasher et al., "Primary structure of the Aequorea victoris green-fluorescent protein," Gene 111: 229-233 (1992) | | | |
| | JL | Proudfoot, A.E.I. et al., "Strategies for Chemokine Antagonists as Therapeutics", Seminars in Immunology, 15: 57-65 (2003) | | | |
| | JM | Puhlmann et al. "Thymidine kinase-deleted vaccinia virus expressing purine nucleoside phosphorylase as a vector for tumor-directed gene therapy." Hum Gene Ther. 10(4):649-57 (1999) | | | |
| | JN | Quenelle, D.C. et al., "Efficacy of Multiple- or Single-Dose Cidofovir against Vaccinia and Cowpox Virus Infections in Mice", Antimicrobial Agents and Chemotherapy, 47(10): 3275-3280 (2003) | | | |
| | JO | Ramirez, J.C. et al., "Tissue distribution of the Ankara strain of vaccinia virus (MVA) after mucosal or systemic administration", Arch. Virol., 148: 827-839 (2003) | | | |
| | JP | Rangarajan, A. and R.A. Weinberg, "Comparative biology of mouse versus human cells: modeling human cancer in mice", Nature Reviews Cancer, 3: 952-959 (2003) | | | |
| | JQ | Ransohoff, R.M. et al., "Three or more routes for leukocyte migration into the central nervous system", Nat. Rev. Immunol., 3: 569-581 (2003) | | | |
| | JR | Reddy et al. "Folate-mediated targeting of therapeutic and imaging agents to cancers," Crit Rev Ther Drug Carrier Syst. 15(6):587-627 (1998) | | | |
| | JS | Reno, F., "Non-clinical Toxicology", Principles and Practice of Pharmaceutical Medicine, A.J. Fletcher et al.(eds.), ch.6: 55-64 (c2002) John Wiley & Sons Ltd. | | | |
| | JT | Ribas, A. et al., "Current Developments in Cancer Vaccines and Cellular Immunotherapy", Journal of Clinical Oncology, 21(12): 2415-2432 (2003) | | | |
| | JU | Ring, C.J.A., "Cytolytic viruses as potential anti-cancer agents", J. Gen. Virol., 83: 491-502 (2002) | | | |
| | JV | Rodriguez, J.F. et al., "Expression of the firefly luciferase gene in vaccinia virus: A highly sensitive gene marker to follow virus dissemination in tissues of infected animals," Proc. Natl. Acad. Sci. U.S.A., 85: 1667-1671 (1988) | | | |
| | JW | Rothenberg, M.L. et al., "Improving the evaluation of new cancer treatments: challenges and opportunities", Nat. Rev. Cancer, 3: 303-309 (2003) | | | |
| | JX | Ruef et al. "Sternal wound infection after heart operations in pediatric patients associated with nasal carriage of <i>Staphylococcus aureus</i> " J. of Thoracic and Cardiovascular Surgery 112(3): 681-686 (1996) | | | |
| | JY | Santoro, J. and M.E. Levison, "Rat Model of Experimental Endocarditis," Infect. Immun. 19(3): 915-918 (1978) | | | |
| <i>V</i> | JZ | Schlör et al., "In vivo and in vitro studies on interactions between the components of the hemolysin (HlyA) secretion machinery of <i>Escherichia coli</i> ," Mol.Gen.Genet. 256: 306-319 (1997) | | | |
| <i>MK</i> | KA | Schmidt et al. "Generation of effective cancer vaccines genetically engineered to secrete cytokines using adenovirus-enhanced transferrin infection (AVET)," Gene. 190(1):211-6 (1997) | | | |
| Examiner Signature <i>R. Kelly</i> | | | Date Considered <i>6/2/06</i> | | |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | |

| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | | Attorney's Docket No. 17248-004002 | Application No. 10/849,664 |
|---|--------------|--|--|---------------------------------------|-------------------------------|
| List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | | | | Applicant Szalay, et al. | |
| | | | | Filing Date May 19, 2004 | Group Art Unit 1632-1633 |
| Other Documents (include Author, Title, Date, and Place of Publication) | | | | | |
| Examiner Initial | Desig. ID | Document | | | |
| <i>TK</i> | KB | Shapiro, D. and A.W. Fox, "Biotechnology Products and Their Development", Principles and Practice of Pharmaceutical Medicine, A.J. Fletcher, et al.(eds.), ch.17: 191-201, c2002 John Wiley & Sons | | | |
| | KC | Shariatmadari et al., "Improved technique for detection of enhanced green fluorescent protein in transgenic mice," Biotechniques 30:1282-1285 (2001) | | | |
| | KD | Shata, M.T. et al., "Optimization of recombinant vaccinia-based ELISPOT assay", J. Immunological Methods, 283: 281-289 (2003) | | | |
| | KE | Shenk, T., "Delivery systems for gene therapy: the adenovirus", Stem Cell Biology and Gene Therapy, Quesenberry, P.J. et al. (Eds.), ch.6: pp 161-178, c1998 Wiley-Liss, Inc. | | | |
| | KF | Shepherd, A.J., "Good Laboratory Practice in the Research and Development Laboratory", Gene Therapy Technologies, Applications and Regulations, A. Meager (Ed.), ch.19: 375-381 (c1999) John Wiley & Sons Ltd. | | | |
| | KG | Shimizu, Y. et al., "Immunotherapy of tumor-bearing mice utilizing virus help", Cancer Immunol. Immunother., 27: 223-227 (1988) | | | |
| | KH | Sinkovics, J. and J. Horvath, "New Developments in the Virus Therapy of Cancer: A Historical Review", Intervirology, 36: 193-214 (1993) | | | |
| | KI | Sinkovics, J.G. and J.C. Horvath, "Newcastle disease virus (NDV): brief history of its oncolytic strains", J. Clin. Virol., 16: 1-15 (2000) | | | |
| | KJ | Sinkovics, J.G. and J.C. Horvath, "Virus therapy of human cancers", Melanoma Research, 13: 431-432 (2003) | | | |
| | KK | Smee, D.F. and R.W. Sidwell, "A review of compounds exhibiting anti-orthopoxvirus activity in animal models", Antiviral Research, 57: 41-52 (2003) | | | |
| | KL | Smee, D.F. et al., "Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice", Antivir. Res., 52: 55-62 (2001) | | | |
| | KM | Smith, G.L. and B. Moss, "Infectious poxvirus vectors have capacity for at least 25000 base pairs of foreign DNA", Gene, 25: 21-28 (1983) | | | |
| | KN | Smith, G.L. et al., "The formation and function of extracellular enveloped vaccinia virus", J. Gen. Virol., 83: 2915-2931 (2002) | | | |
| | KO | Somia, N. and I.M. Verma, "Gene Therapy: Trial and Tribulations", Nat. Rev. Genet., 1(2): 91-99 (2000) | | | |
| | KP | Spencer et al., "Unilateral Transplantation of Human Fetal Mesencephalic Tissue Into The Caudate Nucleus Of Patients with Parkinson's Disease", New England Journal of Medicine 327: 1541-1548 (1992) | | | |
| | KQ | Stehle, G. et al., "Plasma protein (albumin) catabolism by the tumor itself--implications for tumor metabolism and the genesis of cachexia", Critical Reviews in Oncology/Hematology, 26: 77-100 (1997) | | | |
| <i>V</i> | KR | Stojdl, D.F. et al., "VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents", Cancer Cell, 4:263-275 (2003) | | | |
| | KS | Sudimack et al. "Targeted drug delivery via the folate receptor." Adv Drug Deliv Rev. 41(2):147-62 (2000) | | | |
| <i>TK</i> | KT | Sutton et al. "In vivo adenovirus-mediated suicide gene therapy of orthotopic bladder cancer." Mol Ther. 2(3):211-7 (2000) | | | |

| | |
|---|---------------------------|
| Examiner Signature <i>[Signature]</i> | Date Considered 6/2/06 |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | | Attorney's Docket No. 17248-004002 | Application No. 10/849,664 |
|---|--------------|---|--|---------------------------------------|-------------------------------|
| List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | | | | Applicant Szalay, et al. | |
| | | | | Filing Date May 19, 2004 | Group Art Unit 1632-1633 |
| Other Documents (include Author, Title, Date, and Place of Publication) | | | | | |
| Examiner Initial | Desig. ID | Document | | | |
| MK | KU | Suzuki M., Szalay A.A., "Bacterial transformation using temperature-sensitive mutants deficient in peptidoglycan synthesis," Methods Enzymol. 68:331-342 (1979) | | | |
| | KV | Suzuki, S. et al. "Coexpression of the partial androgen receptor enhances the efficacy of prostate-specific antigen promoter-driven suicide gene therapy for prostate cancer cells at low testosterone concentrations," Cancer Research 61(4):1276-1279 (2001) | | | |
| | KW | Symons, J.A. et al., "A study of the vaccinia virus interferon-γ receptor and its contribution to virus virulence", Journal of General Virology, 83: 1953-1964 (2002) | | | |
| | KX | Szalay A.A. et al., "Separation of the complementary strands of DNA fragments on polyacrylamide gels," Nucleic Acids Res. 4(5):1569-78 (1977) | | | |
| | KY | Szalay A.A. et al, "Genetic engineering of halotolerance in microorganisms: a summary," Basic Life Sci. 14:321-32 (1979) | | | |
| | KZ | Technology Evaluation Center, "Special Report: Vaccines for the Treatment of Malignant Melanoma", TEC Assessment Program, 16(4): 1-46 (2001) | | | |
| | LA | t'Hart, B.A. et al., "Gene therapy in nonhuman primate models of human autoimmune disease", Gene Therapy, 10: 890-901 (2003) | | | |
| | LB | Theuer et al., "A recombinant form of pseudomonas exotoxin directed at the epidermal growth factor receptor that is cytotoxic without requiring proteolytic processing," J.Biol.Chem. 267(24): 16872-16877 (1992) | | | |
| | LC | Timiryasova, T.M. et al., "Antitumor Effect of Vaccinia Virus in Glioma Model", Oncology Research, 11(3): 133-144 (1999) | | | |
| | LD | Timiryasova, T.M. et al., "Replication-deficient vaccinia virus gene therapy vector: evaluation of exogenous gene expression mediated by PUV-inactivated virus in glioma cells", Journal of Gene Medicine, 3: 468-477 (2001) | | | |
| | LE | Timiryasova, T.M. et al., "Vaccinia virus-mediated expression of wild-type p53 suppresses glioma cell growth and induces apoptosis." Int J Oncol. 14(5):845-54 (1999) | | | |
| | LF | Timiryasova, T.M. et al., "Visualization of Vaccinia Virus Infection Using the Renilla-Luciferase-GFP Fusion Protein", Bioluminescence & chemiluminescence: Proceedings of the 11th International Symposium on Bioluminescence Chemiluminescence: Asilomar Conference Grounds, Pacific Grove, Monterey, California: September 6-10 2000 / (eds.): Case, J.F. et al., World Scientific Publishing Co. (c2001), pages 457-460 | | | |
| | LG | Timpl, "Antibodies to Collagens and Procollagens," Methods Enzymol. 82: 472-498 (1982) | | | |
| | LH | Tjuvajev, J. et al., "Salmonella-based tumor-targeted cancer therapy: tumor amplified protein expression therapy (TAPET™) for diagnostic imaging," J. Controlled Release, 74: 313-315 (2001) | | | |
| | LI | Toguchi et al., "Suicide Gene Therapy of C6 Glioma Cells Mediated by Replication-Deficient and Replication Competent Vaccinia Viruses," Cancer Gene Therapy 10: S32 (2003) presented at the Eleventh International Conference on Gene Therapy of Cancer, December 12-14, 2002, San Diego California | | | |
| | LJ | Tokugawa et al., "A model system for the continuous production of a heterologous protein using a novel secretion promoting factor which operates in Escherichia coli," J.Biotechnol. 37:33-37 (1994) | | | |
| | LK | Tokugawa et al., "A novel protein secretion factor from a Vibrio species which operates in Escherichia coli," J.Biotechnol. 35: 69-76 (1994) | | | |
| MK | LL | Tonetti DA et al "Stable transfection of an estrogen receptor beta cDNA isoform into MDA-MB-231 breast cancer cells," J Steroid Biochem Mol Biol. 87(1):47-55(2003) | | | |
| Examiner Signature | | Date Considered | | | |
| [Signature] | | 6/2/06 | | | |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | |

| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | | Attorney's Docket No. 17248-004002 | Application No. 10/849,664 |
|---|--------------|---|--|---------------------------------------|-------------------------------|
| List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | | | | Applicant Szalay, et al. | |
| | | | | Filing Date May 19, 2004 | Group Art Unit 1632-1633 |
| Other Documents (include Author, Title, Date, and Place of Publication) | | | | | |
| Examiner Initial | Desig. ID | Document | | | |
| MK | LM | Tresco et al., "Polymer-encapsulated PC12 Cells: Long-Term Survival and Associated Reduction in Lesion-Induced Rotational Behavior", <i>Cell Transplantation</i> 1:255-264 (1992) | | | |
| | LN | Tscharke, D.C. et al., "A model for vaccinia virus pathogenesis and immunity based on intradermal injection of mouse ear pinnae", <i>J. Gen. Virol.</i> , 80: 2751-2755 (1999) | | | |
| | LO | Tscharke, D.C. et al., "Dermal infection with vaccinia virus reveals roles for virus proteins not seen using other inoculation routes", <i>Journal of General Virology</i> , 83: 1977-1986 (2002) | | | |
| | LP | Tseng, J.-C. et al., "In Vivo Antitumor Activity of Sindbis Viral Vectors", <i>Journal of the National Cancer Institute</i> , 94(23): 1790-1802 (2002) | | | |
| | LQ | Tseng, J.-C. et al., "Systemic tumor targeting and killing by Sindbis viral vectors", <i>Nat. Biotechnol.</i> , 22(1): 70-77 (2004) | | | |
| | LR | Tsung, K. et al., "Immune Response Against Large Tumors Eradicated by Treatment with Cyclophosphamide and IL-12", <i>J. Immunol.</i> , 160: 1369-1377 (1998) | | | |
| | LS | Vanderplasschen, A. et al., "Antibodies against vaccinia virus do not neutralize extracellular enveloped virus but prevent virus release from infected cells and comet formation", <i>Journal of General Virology</i> , 78: 2041-2048 (1997) | | | |
| | LT | Vanderplasschen, A. et al., "Intracellular and extracellular vaccinia virions enter cells by different mechanisms", <i>Journal of General Virology</i> , 79: 877-887 (1998) | | | |
| | LU | Varghese, S. and S.D. Rabkin, "Oncolytic herpes simplex virus vectors for cancer virotherapy", <i>Cancer Gene Therapy</i> , 9: 967-978 (2002) | | | |
| | LV | Vento, S. and F. Cainelli, "Infections in patients with cancer undergoing chemotherapy: aetiology, prevention, and treatment", <i>Lancet</i> , 4: 595-604 (2003) | | | |
| | LW | Vestweber, D., "Regulation of endothelial cell contacts during leukocyte extravasation", <i>Curr. Opin. Cell Biol.</i> , 14: 587-593 (2002) | | | |
| | LX | Vile, R. et al., "The oncolytic virotherapy treatment platform for cancer: Unique biological and biosafety points to consider", <i>Cancer Gene Therapy</i> , 9: 1062-1067 (2002) | | | |
| | LY | Vogel, J.R., "Outsourcing Clinical Drug Development Activities to Contract Research Organizations (CROs): Critical Success Factors", <i>Principles and Practice of Pharmaceutical Medicine</i> , A.J. Fletcher et al.(eds.), ch.40: 461-482 (c2002) John Wiley & Sons Ltd. | | | |
| | LZ | Voisey et al. Elimination of internal restriction enzyme sites from a bacterial luminescence (luxCDABE) operon." <i>Biotechniques</i> 24(1):56, 58 (1998) | | | |
| | MA | Wallack, M.K. et al., "A Phase III Randomized, Double-Blind, Multiinstitutional Trial of Vaccinia Melanoma Oncolysate-Active Specific Immunotherapy for Patients with Stage II Melanoma", <i>Cancer</i> , 75(1): 34-42 (1995) | | | |
| | MB | Wallack, M.K. et al., "Increased Survival of Patients Treated With a Vaccinia Melanoma Oncolysate Vaccine", <i>Annals of Surgery</i> , 226(2): 198-206 (1997) | | | |
| | MC | Wallack, M.K. et al., "Surgical Adjuvant Active Specific Immunotherapy for Patients with Stage III Melanoma: The Final Analysis of Data From a Phase III, Randomized, Double-Blind, Multicenter Vaccinia Melanoma Oncolysate Trial", <i>J. Am. Coll. Surg.</i> , 187(1): 69-79 (1998) | | | |
| MK | MD | Wang Y. et al., "A study of protein-protein interactions in living cells using luminescence resonance energy transfer (LRET) from <i>Renilla</i> luciferase to <i>Aequorea</i> GFP," <i>Mol Gen Genet.</i> 264(5):578-87 (2001) | | | |

| | |
|---|---------------------------|
| Examiner Signature  | Date Considered 6/2/06 |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | | Attorney's Docket No. 17248-004002 | Application No. 10/849,664 |
|---|--------------|--|--|---------------------------------------|--|
| List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | | | | Applicant Szalay, et al. | |
| | | | | Filing Date May 19, 2004 | Group Art Unit 1632 1633 |
| Other Documents (include Author, Title, Date, and Place of Publication) | | | | | |
| Examiner Initial | Desig. ID | Document | | | |
| MK | ME | Wang Y. et al., "Renilla luciferase- Aequorea GFP (Ruc-GFP) fusion protein, a novel dual reporter for real-time imaging of gene expression in cell cultures and in live animals," Mol Genet Genomics. 268(2):160-8 (2002) | | | |
| | MF | Wang, Y. et al., "The Renilla Luciferase-Modified GFP Fusion Protein is Functional in Transformed Cells", Bioluminescence & chemiluminescence: Proceedings of the 9th International Symposium on Bioluminescence Chemiluminescence: Woods Hole, Massachusetts, October 1996 / (eds.) Hastings, J.W. et al., John Wiley & Sons Ltd. (c1997) | | | |
| | MG | Warrington et al. "Developing VDEPT for DT-diaphorase (NQO1) using an AAV vector plasmid," Int J Radiat Oncol Biol Phys. 42(4):909-12 (1998) | | | |
| | MH | Wegner et al., "Cis-acting sequences from mouse rDNA promote plasmid DNA amplification and persistence in mouse cells: implication of HMG-I in their function", Nucleic Acids Research 17:9909-9932 (1989) | | | |
| | MI | Weissleder et al. "Drug targeting in magnetic resonance imaging," Magnetic Resonance Quarterly. 8(1):55-63 (1992) | | | |
| | MJ | Weissleder, T. et al., "In vivo magnetic resonance imaging of transgene expression", Nat. Med. , 6(3): 351-354 (2000) | | | |
| | MK | Welling et al "Technetium-99m labelled antimicrobial peptides discriminate between bacterial infections and sterile inflammations." Eur J Nucl Med. 27(3):292-301 (2000) | | | |
| | ML | Welling et al "Radiochemical and biological characteristics of 99mTc-UBI 29-41 for imaging of bacterial infections." Nucl Med Biol. 29(4):413-22 (2002) | | | |
| | MM | West et al. "Identification of a somatodendritic targeting signal in the cytoplasmic domain of the transferrin receptor." J Neurosci. 17(16):6038-47 (1997) | | | |
| | MN | Wharton, M. et al., "Recommendations for Using Smallpox Vaccine in a Pre-Event Vaccination Program", MMWR, 52(RR-7): 1-16 (2003) | | | |
| | MO | Whitley, R.J., "Smallpox: a potential agent of bioterrorism", Antiviral Research 57: 7-12 (2003) | | | |
| | MP | Williams J.G. and Szalay A.A., "Stable integration of foreign DNA into the chromosome of the cyanobacterium <i>Synechococcus</i> R2," Gene. 24(1):37-51 (1983). | | | |
| | MQ | Winn et al., "Behavioral Recovery following Intrastriatal Implantation of Microencapsulated PC12 Cells", Experimental Neurology 113:322-329 (1991) | | | |
| | MR | Winn, S.R. et al., Polymer-encapsulated cells genetically modified to secrete human nerve growth factor promote the survival of axotomized septal cholinergic neurons," Proceedings of the National Academy of Science, 91:2324-2328 (1994). | | | |
| | MS | Wisher, M., "Biosafety and product release testing issues relevant to replication-competent oncolytic viruses", Cancer Gene Therapy, 9: 1056-1061 (2002) | | | |
| | MT | Wittrup, D., "Tumor Targeting Theory", IBC's 15 th Annual International Antibody Engineering Conference entitled Antibody Engineering: Forging the Future of Antibody Therapeutics, November 30 - December 3, 2003 - The Paradise Point Resort - San Diego, CA, pp. 1-17 | | | |
| V | MU | Wlodaver, C.G. et al., "Laboratory-acquired vaccinia infection", Journal of Clinical Virology, xxx: 1-5 (2003) | | | |
| MK | MV | Wong, M.M. and E.N. Fish, "Chemokines: attractive mediators of the immune response", Semin. Immunol. 15: 5-14 (2003) | | | |

Examiner Signature

R. N. Kelly

Date Considered

6/2/06

EXAMINER: Initial if citation considered; whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 17248-004002 | Application No. 10/849,664 |
|---|--------------|---|---------------------------------------|-------------------------------|
| List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | | | Applicant Szalay, et al. | |
| | | | Filing Date May 19, 2004 | Group Art Unit 1632-1633 |
| Other Documents (include Author, Title, Date, and Place of Publication) | | | | |
| Examiner Initial | Desig. ID | Document | | |
| <i>RJK</i> | MW | Yadav, R. et al., "Migration of leukocytes through the vessel wall and beyond," Thromb. Haemost., 90: 598-606 (2003) | | |
| | MX | Yansura, D.G. and Henner D.J., "Use of the Escherichia coli lac repressor and operator to control gene expression in Bacillus subtilis," Proc. Natl. Acad. Sci USA 81: 439-443 (1984) | | |
| | MY | Yu Y.A., "Visualization of molecular and cellular events with green fluorescent proteins in developing embryos: a review," Luminescence. 18(1):1-18 (2003) Erratum in: Luminescence. 2003 Jul-Aug;18(4):243 | | |
| | MZ | Yu Y.A. et al., "A Renilla luciferase-Aequorea GFP (ruc-gfp) fusion gene construct permits real-time detection of promoter activation by exogenously administered mifepristone in vivo," Mol Genet Genomics. 268(2):169-78 (2002) | | |
| | NA | Yu Y.A. et al., "Optical imaging: bacteria, viruses, and mammalian cells encoding light-emitting proteins reveal the locations of primary tumors and metastases in animals," Anal Bioanal Chem. 377(6):964-72 (2003) | | |
| | NB | Yu, Y.A. et al. "Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins," Nat Biotech. 22(3): 313-320 (2004) | | |
| | NC | Yun A.C. et al. "Nitrogenase promoter-lacZ fusion studies of essential nitrogen fixation genes in Bradyrhizobium japonicum 1110," J Bacteriol. 167(3):784-91 (1986) | | |
| | ND | Zamir et al. "Stable chromosomal integration of the entire nitrogen fixation gene cluster from Klebsiella pneumoniae in yeast," Proc Natl Acad Sci U S A. 78(6):3496-500 (1981) | | |
| | NE | Zauchar, G.M. et al., "The Pathology of Experimental Aerosolized Monkeypox Virus Infection in Cynomolgus Monkeys (Macaca fascicularis)," Lab. Invest., 81: 1581-1600 (2001) | | |
| | NF | Zeh, H.J. and D.L. Bartlett, "Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers," Cancer Gene Therapy, 9: 1001-1012 (2002) | | |
| | NG | Zhang et al., "Urothelium-specific Expression of an Oncogene in Transgenic Mice Induced the Formation of Carcinoma in Situ and Invasive Transitional Cell Carcinoma," Cancer Res. 59: 3512-3517 (1999) | | |
| | NH | Zhu et al., "Smad3 Mutant Mice Develop Metastatic Colorectal Cancer," Cell 94: 703-714 (1998) | | |
| <i>V</i> | NI | Zinkernagel, R.M., "Uncertainties--discrepancies in immunology," Immunological Reviews, 185: 103-125 (2002) | | |
| | NJ | Zinn et al., "Simultaneous evaluation of dual gene transfer to adherent cells by gamma-ray imaging," Nuclear Medicine and Biology 28(2):135-144 (2001) | | |
| <i>AMK</i> | NK | Zinn et al. "Noninvasive monitoring of gene transfer using a reporter receptor imaged with a high-affinity peptide radiolabeled with 99mTc or 188Re," J Nucl Med. 2000 May;41(5):887-95. | | |

| | |
|---|---------------------------|
| Examiner Signature <i>R. J. Kelly</i> | Date Considered 6/2/06 |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

| | | | |
|---|---|---|-------------------------------|
| Substitute Form PTO-1449 (Modified) List of Patents and Publications for Applicant's Information & Disclosure Statement (37 CFR §1.98(b)) | U.S. Department of Commerce Patent and Trademark Office AUG 04 2005 RECEIVED | Attorney's Docket No. 17248-004002/4804B | Application No. 10/849,664 |
| | Applicant Szalay et al. | | |
| | Filing Date May 19, 2004 | Group Art Unit 1632 / 633 | |

U.S. Patent Documents

| Examiner Initial | Desig. ID | Document Number | Publication Date | Patentee | Class | Subclass | Filing Date If Appropriate |
|------------------|-----------|-----------------|------------------|-----------------|-------|----------|----------------------------|
| RUK | A | 20050031643 | 02/10/05 | Szalay et al. | 424 | 199.1 | 06/18/04 |
| ↓ | B | 20040234455 | 11/25/04 | Szalay et al. | 424 | 9.6 | 06/10/04 |
| | C | 20040213741 | 10/28/04 | Szalay et al. | 424 | 9.6 | 05/19/04 |
| | D | 20050069491 | 3/31/05 | Yu, Yong et al. | 424 | 1.11 | 11/05/04 |
| ↓ | E | 5,646,298 | 07/08/97 | Powell et al. | 548 | 427 | 06/07/95 |
| RUK | F | 6,491,905 | 12/10/02 | Sorscher et al. | 435 | 325 | 10/30/98 |

Foreign Patent Documents or Published Foreign Patent Applications

| Examiner Initial | Desig. ID | Document Number | Publication Date | Country or Patent Office | Class | Subclass | Translation | |
|------------------|-----------|-----------------|------------------|--------------------------|-------|----------|-------------|----|
| | | | | | | | Yes | No |
| RUK | G. | EP 1 512 746 | 03/09/2005 | EP | | | | |
| ↓ | H. | EP 1 526 185 | 04/27/05 | EP | | | | |
| | I. | WO 00/73479 | 12/07/2000 | PCT | | | | |
| | J. | WO 88/00617 | 01/28/1988 | PCT | | | | |
| | K. | WO 90/13658 | 11/15/1990 | PCT | | | | |
| | L. | WO 92/22327 | 12/23/1992 | PCT | | | | |
| ↓ | M. | WO 96/40238 | 12/19/1996 | PCT | | | | |
| | N. | WO 97/40183 | 10/30/1997 | PCT | | | | |
| RUK | O. | WO 98/14605 | 04/09/1998 | PCT | | | | |

Other Documents (include Author, Title, Date, and Place of Publication)

| Examiner Initial | Desig. ID | Document |
|------------------|-----------|---|
| RUK | P. | Aboody et al., "Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas," Proc Natl Acad Sci U S A. 97(23):12846-51 (2000) |
| | Q. | Aksac S., "[Antibody formation against Agrobacterium tumefaciens in patients with various cancers]," Turk Hij Tecr Biyol Derg. 34(1-2):48-51 (1974) [Article in Italian]. |
| | R. | Altshstein et al., "[Isolation of a recombinant vaccinia virus based on the LIVP strain inducing the surface antigen of the hepatitis B virus]," Dokl Akad Nauk SSSR. 285(3):696-9 (1985) [Article in Russian]. |
| RUK | S. | Anaissie et al., "Pseudomonas putida. Newly recognized pathogen in patients with cancer," Am J Med. 82(6):1191-4 (1987) |
| RUK | T. | Anand, A and A.E. Glatt, "Clostridium difficile infection associated with antineoplastic chemotherapy: a review," Clin Infect Dis. 17(1):109-13 (1993) |

Examiner Signature

Robert J. Kelly

Date Considered

6/2/06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | | Attorney's Docket No. 17248-004002/4804B | Application No. 10/849,664 |
|---|--------------|---|--|---|---|
| List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | | | | Applicant Szalay et al. | |
| | | | | Filing Date May 19, 2004 | Group Art Unit 1632 / 633 |
| Other Documents (include Author, Title, Date, and Place of Publication) | | | | | |
| Examiner Initial | Desig. ID | Document | | | |
| DMK | U. | Arab et al., "Verotoxin induces apoptosis and the complete, rapid, long-term elimination of human astrocytoma xenografts in nude mice," Oncol Res. 11(1):33-9 (1999) | | | |
| | V. | Arakawa et al., "Clinical trial of attenuated vaccinia virus AS strain in the treatment of advanced adenocarcinoma. Report on two cases," J Cancer Res Clin Oncol. 113(1):95-8 (1987) | | | |
| | W. | ATCC Accession No. 11842 | | | |
| | X. | ATCC Accession No. 11863 | | | |
| | Y. | ATCC Accession No. 13124 | | | |
| | Z. | ATCC Accession No. 15696 | | | |
| | AA. | ATCC Accession No. 15697 | | | |
| | AB. | ATCC Accession No. 15707 | | | |
| | AC. | ATCC Accession No. 15955 | | | |
| | AD. | ATCC Accession No. 17583 | | | |
| | AE. | ATCC Accession No. 17836 | | | |
| | AF. | ATCC Accession No. 19401 | | | |
| | AG. | ATCC Accession No. 19402 | | | |
| | AH. | ATCC Accession No. 19404 | | | |
| | AI. | ATCC Accession No. 25527 | | | |
| | AJ. | ATCC Accession No. 25752 | | | |
| | AK. | ATCC Accession No. 25923 | | | |
| | AL. | ATCC Accession No. 27337 | | | |
| | AM. | ATCC Accession No. 27555 | | | |
| | AN. | ATCC Accession No. 29212 | | | |
| | AO. | ATCC Accession No. 35782 | | | |
| | AP. | ATCC Accession No. 3624 | | | |
| | AQ. | ATCC Accession No. 37253 | | | |
| | AR. | ATCC Accession No. 393 | | | |
| | AS. | ATCC Accession No. 43142 | | | |
| | AT. | ATCC Accession No. 47054 | | | |
| ↓ | AU. | ATCC Accession No. 51299 | | | |
| Examiner Signature Robert I. Kelly | | | | Date Considered 6/2/06 | |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | |

| | | | | | | | |
|---|--------------|--|--|---|--|-------------------------------|--|
| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | | Attorney's Docket No. 17248-004002/4804B | | Application No. 10/849,664 | |
| List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | | | | Applicant Szalay et al. | | | |
| | | | | Filing Date May 19, 2004 | | Group Art Unit 1632 / 633 | |
| | | | | | | | |
| Other Documents (include Author, Title, Date, and Place of Publication) | | | | | | | |
| Examiner Initial | Desig. ID | Document | | | | | |
| 24K | AV. | ATCC Accession No. 700057 | | | | | |
| | AW. | ATCC Accession No. 824 | | | | | |
| | AX. | ATCC Accession No. 9338 | | | | | |
| | AY. | ATCC Accession No. 9714 | | | | | |
| | AZ. | ATCC Accession No. BAA-250D | | | | | |
| | BA. | ATCC Accession No. CCL-70 | | | | | |
| | BB. | Azmi et al., "In situ localization of endogenous cytokinins during shooty tumor development on <i>Eucalyptus globulus</i> Labill," <i>Planta</i> 213(1):29-36 (2001) | | | | | |
| | BC. | Baker, S.J. and E.P. Reddy, "Transducers of life and death: TNF receptor superfamily and associated proteins," <i>Oncogene</i> 12(1):1-9 (1996) | | | | | |
| | BD. | Banerjee et al., " <i>Bacillus</i> infections in patients with cancer," <i>Arch Intern Med.</i> 148(8):1769-74 (1988) | | | | | |
| | BE. | Bentires-Alj et al., "Cytosine deaminase suicide gene therapy for peritoneal carcinomatosis," <i>Cancer Gene Ther.</i> 7(1):20-6 (2000) | | | | | |
| | BF. | Bermudes et al., "Tumor-targeted <i>Salmonella</i> : Highly selective delivery vectors," <i>Adv Exp Med Biol.</i> 465:57-63 (2000) | | | | | |
| | BG. | Beyer et al., "Oncoretrovirus and lentivirus vectors pseudotyped with lymphocytic choriomeningitis virus glycoprotein: generation, concentration, and broad host range," <i>J Virol.</i> 76(3):1488-95 (2002) | | | | | |
| | BH. | Biffi et al., "Antiproliferative effect of fermented milk on the growth of a human breast cancer cell line," <i>Nutr Cancer.</i> 28(1):93-9 (1997) | | | | | |
| | BI. | Block et al., "Gene therapy of metastatic colon carcinoma: regression of multiple hepatic metastases by adenoviral expression of bacterial cytosine deaminase," <i>Cancer Gene Ther.</i> 7(3):438-45 (2000) | | | | | |
| | BJ. | Bodey et al., "Clostridial bacteremia in cancer patients. A 12-year experience," <i>Cancer</i> 67(7):1928-42 (1991) | | | | | |
| | BK. | Bogdanov et al., "Antitumor glycopeptides from <i>Lactobacillus bulgaricus</i> cell wall," <i>FEBS Lett.</i> 57(3):259-61 (1975) | | | | | |
| | BL. | Bogdanov et al., "Antitumor action of glycopeptides from the cell wall of <i>Lactobacillus bulgaricus</i> ," <i>Bulletin of Experimental Biology and Medicine.</i> 84(12): 1750-1753 (1977); translated from the original Russian article: <i>Byulleten' Éksperimental'noi Biologii i Meditsiny</i> 84(12):709-12 (1977) | | | | | |
| | BM. | Certified English translation of Timiryasova et al., "Analysis of Reporter Gene Expression in Various Regions of the Genome of the Vaccinia Virus," <i>Molecular Biology</i> 27(2): 2-11 (1993). | | | | | |
| | BN. | Chang et al., "Differential apoptotic susceptibility to anti-Fas IgM and anticancer drugs in a human endometrial adenocarcinoma cell line HHUA on laminin and type I collagen," <i>Osaka City Med J.</i> 44(2):173-80 (1998) | | | | | |
| | BO. | Chatterjee, B.D. and C.K. Chakraborti, "Non-sporing anaerobes in certain surgical group of patients," <i>J Indian Med Assoc.</i> 93(9):333-5, 339 (1995) | | | | | |
| ↓ | BP. | Chen et al., "Low-dose vaccinia virus-mediated cytokine gene therapy of glioma," <i>J Immunother.</i> 24(1):46-57 (2001) | | | | | |
| 24K | BQ. | Clairmont et al., "Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of <i>Salmonella typhimurium</i> ," <i>J Infect Dis.</i> 181(6):1996-2002 (2000) | | | | | |
| Examiner Signature Robert A. Kelly | | | | Date Considered 6/2/06 | | | |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | |

| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | | Attorney's Docket No. 17248-004002/4804B | Application No. 10/849,664 |
|--|--------------|---|---|---|--------------------------------|
| List of Patents and Publications for Applicant's Information Disclosure Statement | | | | Applicant Szalay et al. | |
| | | | | Filing Date May 19, 2004 | Group Art Unit 4632 / 6 3 3 |
| (37 CFR §1.98(b)) | | | | | |
| Other Documents (include Author, Title, Date, and Place of Publication) | | | | | |
| Examiner Initial | Desig. ID | Document | | | |
| MK | BR. | Cole, A.M. and T. Ganz, "Human antimicrobial peptides: analysis and application," Biotechniques. 29(4):822-6, 828, 830-1 (2000) | | | |
| | BS. | Collins, J.L. and C.J. Wust, "Suppression of SV40 tumors after immunization with group A Streptococcus pyogenes and Bordetella pertussis," Cancer Res. 34(5):932-7 (1974) | | | |
| | BT. | Dang et al., "Combination bacteriolytic therapy for the treatment of experimental tumors," Proc Natl Acad Sci U S A. 98(26):15155-60 (2001) | | | |
| | BU. | de Lorenzo V., "Isolation and characterization of microcin E492 from Klebsiella pneumoniae," Arch Microbiol. 139(1):72-5 (1984) | | | |
| | BV. | Djeha et al., "Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954," Cancer Gene Ther. 7(5):721-31 (2000) | | | |
| | BW. | Djeha et al., "Combined adenovirus-mediated nitroreductase gene delivery and CB1954 treatment: a well-tolerated therapy for established solid tumors. Mol Ther. 2001 Feb;3(2):233-40. | | | |
| | BX. | Duncan, J.R. and M.J. Welch, "Intracellular metabolism of indium-111-DTPA-labeled receptor targeted proteins," J Nucl Med. 34(10):1728-38 (1993) | | | |
| | BY. | Dunn et al., "Cancer immunoediting: from immunosurveillance to tumor escape.," Nat Immunol. 3(11):991-8 (2002) | | | |
| | BZ. | Eliopoulos et al., "CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily," Mol Cell Biol. 20(15):5503-15 (2000) | | | |
| | CA. | Essbauer, S. and W. Ahne, "Viruses of lower vertebrates," J Vet Med B Infect Dis Vet Public Health. 48(6):403-75 (2001) | | | |
| | CB. | Farkas-Himsley et al., "The bacterial colicin active against tumor cells in vitro and in vivo is verotoxin 1," Proc Natl Acad Sci U S A. 92(15):6996-7000 (1995) | | | |
| | CC. | Feng et al., "The antitumor activity of a mixed bacterial vaccine against mouse hepatoma," Chinese Pharmaceutical Journal 30(7): 405-407 (1995) [Article in Chinese] | | | |
| | CD. | Fodor et al., "Vaccinia virus mediated p53 gene therapy for bladder cancer in an orthotopic murine model," J. Urol. 173(2):604-9 (2005) | | | |
| | CE. | Friedlos et al., "Three new prodrugs for suicide gene therapy using carboxypeptidase G2 elicit bystander efficacy in two xenograft models," Cancer Res. 62(6):1724-1729 (2002) | | | |
| | CF. | Gnant et al., "Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor-specific gene expression and prolongation of survival in mice," Cancer Res. 59(14):3396-3403 (1999) | | | |
| | CG. | Golstein, P., "Cell death: TRAIL and its receptors," Curr Biol. 7(12):R750-R753 (1997) | | | |
| | CH. | Greco et al., "Development of a novel enzyme/prodrug combination for gene therapy of cancer: horseradish peroxidase/indole-3-acetic acid," Cancer Gene Ther. 7(11):1414-20 (2000) | | | |
| | CI. | Gridley et al., "Evaluation of radiation effects against C6 glioma in combination with vaccinia virus-p53 gene therapy," Int J Oncol. 13(5):1093-8 (1998) | | | |
| | V | CJ. | Gridley et al., "Proton radiation and TNF- α /Bax gene therapy for orthotopic C6 brain tumor in Wistar rats," Technol Cancer Res Treat. 3(2):217-27 (2004) | | |
| CK. | | Grote et al., "Live attenuated measles virus induces regression of human lymphoma xenografts in immunodeficient mice," Blood 97(12):3746-54 (2001) | | | |


| | |
|---|---------------------------|
| Examiner Signature <i>Robert A. Kelly</i> | Date Considered 6/2/06 |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | | Attorney's Docket No. 17248-004002/4804B | Application No. 10/849,664 |
|---|--------------|--|--|---|-------------------------------|
| List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | | | | Applicant Szalay et al. | |
| | | | | Filing Date May 19, 2004 | Group Art Unit 1632 / 633 |
| Other Documents (include Author, Title, Date, and Place of Publication) | | | | | |
| Examiner Initial | Desig. ID | Document | | | |
| ZMK | CL. | Hall et al., "In vitro efficacy of transferrin-toxin conjugates against glioblastoma multiforme," J Neurosurg. 76(5):838-44 (1992) | | | |
| | CM. | Hall et al., "In vivo efficacy of intrathecal transferrin-Pseudomonas exotoxin A immunotoxin against LOX melanoma," Neurosurgery 34(4):649-55; discussion 655-6 (1994) | | | |
| | CN. | Hansen, R.M. and J.A. Libnoch, "Remission of chronic lymphocytic leukemia after smallpox vaccination," Arch Intern Med. 138(7):1137-8 (1978) | | | |
| | CO. | Harrison et al., "Gene-modified PA1-STK cells home to tumor sites in patients with malignant pleural mesothelioma," Ann Thorac Surg. 70(2):407-11 (2000) | | | |
| | CP. | Hasegawa et al., "Avoidance of bone marrow suppression using A-5021 as a nucleoside analog for retrovirus-mediated herpes simplex virus type I thymidine kinase gene therapy," Cancer Gene Ther. 7(4):557-62 (2000) | | | |
| | CQ. | Herrlinger et al., "Neural precursor cells for delivery of replication-conditional HSV-1 vectors to intracerebral gliomas," Mol Ther. 1(4):347-57 (2000) | | | |
| | CR. | Hetz et al., "Microcin E492, a channel-forming bacteriocin from Klebsiella pneumoniae, induces apoptosis in some human cell lines," Proc Natl Acad Sci U S A. 99(5):2696-701 (2002) | | | |
| | CS. | Hostanska et al., "Aqueous ethanolic extract of St. John's wort (Hypericum perforatum L.) induces growth inhibition and apoptosis in human malignant cells in vitro," Pharmazie 57(5):323-31 (2002) | | | |
| | CT. | Hsueh et al., "Outbreak of Pseudomonas fluorescens bacteremia among oncology patients," J Clin Microbiol. 36(10):2914-7 (1998) | | | |
| | CU. | Huang et al., "Impact of liver P450 reductase suppression on cyclophosphamide activation, pharmacokinetics and antitumoral activity in a cytochrome P450-based cancer gene therapy model," Cancer Gene Ther. 7(7):1034-42 (2000) | | | |
| | CV. | Ianaro et al., "A nitric oxide synthase inhibitor reduces inflammation, down-regulates inflammatory cytokines and enhances interleukin-10 production in carrageenin-induced oedema in mice," Immunology. 82(3):370-5 (1994) | | | |
| | CW. | Jiang et al. "Apoptosis in human hepatoma cell lines by chemotherapeutic drugs via Fas-dependent and Fas-independent pathways," Hepatology. 29(1):101-10 (1999) | | | |
| | CX. | Johnson et al., "Improved tumor-specific immunotoxins in the treatment of CNS and leptomeningeal neoplasia," J Neurosurg. 70(2):240-8 (1989) | | | |
| | CY. | Jordan et al., "Melanocyte-Directed enzyme prodrug therapy (MDEPT): development of second generation prodrugs for targeted treatment of malignant melanoma," Bioorg Med Chem. 9(6):1549-58 (2001) | | | |
| | CZ. | Kaklij et al., "Antitumor activity of Streptococcus thermophilus against fibrosarcoma: role of T-cells," Cancer Lett. 56(1):37-43 (1991) | | | |
| | DA. | Kaklij, G.S. and S.M. Kelkar, "Tumor-specific transplantation resistance in mice after treatment of initial tumors with Streptococcus thermophilus," Microbiol Immunol. 40(1):55-8 (1996) | | | |
| | DB. | Kammertoens et al., "Combined chemotherapy of murine mammary tumors by local activation of the prodrugs ifosfamide and 5-fluorocytosine," Cancer Gene Ther. 7(4):629-36 (2000) | | | |
| | DC. | Kan et al., "Direct retroviral delivery of human cytochrome P450 2B6 for gene-directed enzyme prodrug therapy of cancer," Cancer Gene Ther. 8(7):473-82 (2001) | | | |
| ZMK | DD. | Kato et al., "Antitumor activity of Lactobacillus casei in mice," Gann. 72(4):517-23 (1981) | | | |

| | |
|---|---------------------------|
| Examiner Signature  | Date Considered 6/2/06 |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | | Attorney's Docket No. 17248-004002/4804B | | Application No. 10/849,664 | |
|---|--------------|--|--|---|--|--|--|
| List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | | | | Applicant Szalay et al. | | | |
| | | | | Filing Date May 19, 2004 | | Group Art Unit 1632 1633 | |
| Other Documents (include Author, Title, Date, and Place of Publication) | | | | | | | |
| Examiner Initial | Desig. ID | Document | | | | | |
| MK | DE. | Kato et al., "Correlation between increase in Ia-bearing macrophages and induction of T cell-dependent antitumor activity by <i>Lactobacillus casei</i> in mice," Cancer Immunol Immunother. 26(3):215-21 (1988) | | | | | |
| | DF. | Kawamura et al., "Expression of <i>Escherichia coli</i> uracil phosphoribosyltransferase gene in murine colon carcinoma cells augments the antitumoral effect of 5-fluorouracil and induces protective immunity," Cancer Gene Ther. 7(4):637-43 (2000) | | | | | |
| | DG. | Kelkar et al., "Antitumor activity of lactic acid bacteria on a solid fibrosarcoma, sarcoma-180 and Ehrlich ascites carcinoma," Cancer Lett. 42(1-2):73-7 (1988) | | | | | |
| | DH. | Ketlinsky et al., "[Mechanism of the anti-tumoral effect of the blastolysin fraction isolated from <i>Lactobacillus bulgaricus</i>]," Vopr Onkol. 33(3):51-6 (1987) [Article in Russian]. | | | | | |
| | DI. | Kimura et al., "Selective localization and growth of <i>Bifidobacterium bifidum</i> in mouse tumors following intravenous administration," Cancer Res. 40(6):2061-8 (1980) | | | | | |
| | DJ. | Kohwi et al., "Antitumor effect of <i>Bifidobacterium infantis</i> in mice," Gann. 69(5):613-8 (1978) | | | | | |
| | DK. | Kokkinakis et al., "Effect of long-term depletion of plasma methionine on the growth and survival of human brain tumor xenografts in athymic mice," Nutr Cancer. 29(3):195-204 (1997) | | | | | |
| | DL. | Kopylova-Sviridova et al., "Transient expression assay in a baculovirus system using firefly luciferase gene as a reporter," Virus Genes. 6(4):379-86 (1992) | | | | | |
| | DM. | Koyama et al., "Combined suicide gene therapy for human colon cancer cells using adenovirus-mediated transfer of <i>escherichia coli</i> cytosine deaminase gene and <i>Escherichia coli</i> uracil phosphoribosyltransferase gene with 5-fluorocytosine," Cancer Gene Ther. 7(7):1015-22 (2000) | | | | | |
| | DN. | Kunik et al., "Genetic transformation of HeLa cells by <i>Agrobacterium</i> ," Proc Natl Acad Sci U S A. 98(4):1871-6 (2001) | | | | | |
| | DO. | Lachmann, R.H. and S. Efstathiou, "Gene transfer with herpes simplex vectors," Curr Opin Mol Ther. 1(5):622-32 (1999) | | | | | |
| | DP. | Lamensans et al., "Enhancement of immunity against murine syngeneic tumors by a fraction extracted from non-pathogenic mycobacteria," Proc Natl Acad Sci U S A. 72(9):3656-60 (1975) | | | | | |
| | DQ. | Lammertyn et al., "Evaluation of a novel subtilisin inhibitor gene and mutant derivatives for the expression and secretion of mouse tumor necrosis factor alpha by <i>Streptomyces lividans</i> ," Appl Environ Microbiol. 63(5):1808-13 (1997) | | | | | |
| | DR. | Li et al., "Enzyme/prodrug gene therapy approach for breast cancer using a recombinant adenovirus expressing <i>Escherichia coli</i> cytosine deaminase," Cancer Gene Ther. 4(2):113-7 (1997) | | | | | |
| | DS. | Liu et al., "Anticancer efficacy of systemically delivered anaerobic bacteria as gene therapy vectors targeting tumor hypoxia/necrosis," Gene Ther. 9(4):291-6 (2002) | | | | | |
| | DT. | Martino et al., "Bacteremia due to glucose non-fermenting gram-negative bacilli in patients with hematological neoplasias and solid tumors," Eur J Clin Microbiol Infect Dis. 15(7):610-5 (1996) | | | | | |
| | DU. | McIntosh et al., "A probiotic strain of <i>L. acidophilus</i> reduces DMH-induced large intestinal tumors in male Sprague-Dawley rats," Nutr Cancer. 35(2):153-9 (1999) | | | | | |
| | DV. | Meadows et al., "Some biological properties and an in vivo evaluation of tyrosine phenol-lyase on growth of B-16 melanoma," Cancer Res. 36(1):167-7 (1976) | | | | | |
| MK | DW. | Meck et al., "A virus-directed enzyme prodrug therapy approach to purging neuroblastoma cells from hematopoietic cells using adenovirus encoding rabbit carboxylesterase and CPT-11," Cancer Res. 61(13):5083-9 (2001) | | | | | |
| Examiner Signature <i>Robert A. Kelly</i> | | | | Date Considered 6/2/06 | | | |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | |

| | | | | | |
|--|--------------|---|--|---|-------------------------------|
| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | | Attorney's Docket No. 17248-004002/4804B | Application No. 10/849,664 |
| List of Patents and Publications for Applicant's Information Disclosure Statement | | | | Applicant Szalay et al. | |
| | | | | Filing Date May 19, 2004 | Group Art Unit 1632 1633 |
| (37 CFR §1.98(b)) | | | | | |
| Other Documents (include Author, Title, Date, and Place of Publication) | | | | | |
| Examiner Initial | Desig. ID | Document | | | |
| PK | DX. | Micheau et al., "Sensitization of cancer cells treated with cytotoxic drugs to fas-mediated cytotoxicity," J Natl Cancer Inst. 89(11):783-9 (1997) | | | |
| | DY. | Michl et al., "Claudin-4: a new target for pancreatic cancer treatment using <i>Clostridium perfringens</i> enterotoxin," Gastroenterology 121(3):678-84 (2001) | | | |
| | DZ. | Miki et al., "Methioninase gene therapy of human cancer cells is synergistic with recombinant methioninase treatment," Cancer Res. 60(10):2696-702 (2000) | | | |
| | EA. | Milbrandt, E., "A novel source of enterococcal endocarditis," Clin Cardiol. 21(2):123-6 (1998) | | | |
| | EB. | Minton et al., "Chemotherapeutic tumour targeting using clostridial spores," FEMS Microbiol Rev. 17(3):357-64 (1995) | | | |
| | EC. | Mirzadeh et al., "Radiometal labeling of immunoproteins: covalent linkage of 2-(4-isothiocyanatobenzyl)diethylenetriaminepentaacetic acid ligands to immunoglobulin," Bioconjug Chem. 1(1):59-65 (1990) | | | |
| | ED. | Mizutani, T and T. Mitsuoka, "Inhibitory effect of some intestinal bacteria on liver tumorigenesis in gnotobiotic C3H/He male mice," Cancer Lett. 11(2):89-95 (1980) | | | |
| | EE. | Mizutani et al., "Doxorubicin sensitizes human bladder carcinoma cells to Fas-mediated cytotoxicity," Cancer. 79(6):1180-9 (1997) | | | |
| | EF. | Mizutani et al., "Sensitization of human bladder cancer cells to Fas-mediated cytotoxicity by cis-diamminedichloroplatinum (II)," J Urol. 160(2):561-70 (1998) | | | |
| | EG. | Mohr et al., "Rabbit cytochrome P450 4B1: A novel prodrug activating gene for pharmacogene therapy of hepatocellular carcinoma," Cancer Gene Ther. 7(7):1008-14 (2000) | | | |
| | EH. | Moolten, F.L., "Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy," Cancer Res. 46(10):5276-81 (1986) | | | |
| | EI. | Mukherjee et al., "Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation," Cancer Gene Ther. 7(5):663-70 (2000) | | | |
| | EJ. | Murosaki et al., "Antitumor effect of heat-killed <i>Lactobacillus plantarum</i> L-137 through restoration of impaired interleukin-12 production in tumor-bearing mice," Cancer Immunol Immunother. 49(3):157-64 (2000) | | | |
| | EK. | Myklebust et al., "Eradication of small cell lung cancer cells from human bone marrow with immunotoxins," Cancer Res. 53(16):3784-8 (1993) | | | |
| | EL. | Nakamura et al., "Induction of apoptosis in HL60 leukemic cells by anticancer drugs in combination with anti-Fas monoclonal antibody," Anticancer Res. 17(1A):173-9 (1997) | | | |
| | EM. | Nakao, H. and T. Takeda, " <i>Escherichia coli</i> Shiga toxin," J Nat Toxins. 9(3):299-313 (2000) | | | |
| | EN. | Nauciel, C. and A.F. Goguel, "Inhibition of tumor growth by the peptidoglycan from <i>Bacillus megaterium</i> ," J Natl Cancer Inst. 59(6):1723-6 (1977) | | | |
| | EO. | Nuyts et al., "Clostridium spores for tumor-specific drug delivery," Anticancer Drugs. 13(2):115-25 (2002) | | | |
| | EP. | O'Brien et al., "Shiga toxin: biochemistry, genetics, mode of action, and role in pathogenesis," Curr Top Microbiol Immunol. 180:65-94 (1992) | | | |
| PK | EQ. | O'Mahony et al., "Probiotic impact on microbial flora, inflammation and tumour development in IL-10 knockout mice," Aliment Pharmacol Ther. 15(8):1219-25 (2001) | | | |

| | |
|---|---------------------------|
| Examiner Signature  | Date Considered 6/2/06 |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |


| | | | | | | | |
|---|--------------|---|--|---|--|-------------------------------|--|
| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | | Attorney's Docket No. 17248-004002/4804B | | Application No. 10/849,664 | |
| List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | | | | Applicant Szalay et al. | | | |
| | | | | Filing Date May 19, 2004 | | Group Art Unit 1632 / 633 | |
| Other Documents (include Author, Title, Date, and Place of Publication) | | | | | | | |
| Examiner Initial | Desig. ID | Document | | | | | |
| <i>PK</i> | ER. | Paul et al., "Redirected cellular cytotoxicity by infection of effector cells with a recombinant vaccinia virus encoding a tumor-specific monoclonal antibody," Cancer Gene Ther. 7(4):615-23 (2000) | | | | | |
| | ES. | Pawelek et al., "Tumor-targeted <i>Salmonella</i> as a novel anticancer vector," Cancer Res. 57(20):4537-4544 (1997) | | | | | |
| | ET. | Pekhov AA, Zhukova OS, Ivanova TP, Zanin VA, Dobrynin IaV. [Cytotoxic effect of methionine-gamma-lyase on neoplastic cells in culture] Biull Eksp Biol Med. 95(5):87-8 (1983) [Article in Russian]. | | | | | |
| | EU. | Picot et al., " <i>Pseudomonas fluorescens</i> as a potential pathogen: adherence to nerve cells," Microbes Infect. 3(12):985-95 (2001) | | | | | |
| | EV. | Rezmer et al., "Identification and localization of transformed cells in <i>Agrobacterium tumefaciens</i> -induced plant tumors," Planta. 209(4):399-405 (1999) | | | | | |
| | EW. | Saito, H. and T. Watanabe T., "Effects of a bacteriocin from <i>Mycobacterium smegmatis</i> on BALB/3T3 and simian virus 40-transformed BALB/c mouse cells," Microbiol Immunol. 25(1):13-22 (1981) | | | | | |
| | EX. | Schempp et al., "Inhibition of tumour cell growth by hyperforin, a novel anticancer drug from St. John's wort that acts by induction of apoptosis," Oncogene 21(8):1242-50 (2002) | | | | | |
| | EY. | Schirmmacher et al., "Antitumor effects of Newcastle Disease Virus <i>in vivo</i> : local versus systemic effects," Int J Oncol. 18(5):945-52 (2001) | | | | | |
| | EZ. | Schoen et al., "Bacterial delivery of functional messenger RNA to mammalian cells," Cell Microbiol. 7(5):709-24 (2005) | | | | | |
| | FA. | Schroder, J.M., "Epithelial antimicrobial peptides: innate local host response elements," Cell Mol Life Sci. 56(1-2):32-46 (1999) | | | | | |
| | FB. | Schuller et al., "Investigation and management of <i>Clostridium difficile</i> colonisation in a paediatric oncology unit," Arch Dis Child. 72(3):219-222 (1995) | | | | | |
| | FC. | Sekine et al., "Analysis of antitumor properties of effector cells stimulated with a cell wall preparation (WPG) of <i>Bifidobacterium infantis</i> ," Biol Pharm Bull. 18(1):148-53 (1995) | | | | | |
| | FD. | Sekine et al., "A new morphologically characterized cell wall preparation (whole peptidoglycan) from <i>Bifidobacterium infantis</i> with a higher efficacy on the regression of an established tumor in mice," Cancer Res. 45(3):1300-7 (1985) | | | | | |
| | FE. | Sharma et al., "Death the Fas way: regulation and pathophysiology of CD95 and its ligand," Pharmacol Ther. 88(3):333-47 (2000) | | | | | |
| | FF. | Shimizu et al., "Significance of priming of hosts with virus in the tumor-specific immunotherapy model utilizing virus-reactive helper T cell activity," Nippon Gan Chiryo Gakkai Shi. 1989 May 20;24(5):1007-14. [Article in Japanese]. | | | | | |
| | FG. | Shimizu et al., "Immunotherapy of tumor-bearing mice utilizing virus help," Cancer Immunol Immunother. 27(3):223-7 (1988) | | | | | |
| <i>PK</i> | FH. | Simon et al., "Surveillance for nosocomial and central line-related infections among pediatric hematology-oncology patients," Infect Control Hosp Epidemiol. 21(9):592-6 (2000) | | | | | |
| | FI. | Simonds et al., "Deoxyribonucleic acid hybridization among strains of lactobacilli," J Bacteriol. 107(1):382-4 (1971) | | | | | |

| | |
|---|----------------------------------|
| Examiner Signature <i>Rob A. Kelly</i> | Date Considered <i>6/2/06</i> |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP/609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |


| | | | |
|---|--|---|-------------------------------|
| Substitute Form PTO-1449 (Modified) | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 17248-004002/4804B | Application No. 10/849,664 |
| List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | | Applicant Szalay et al. | |
| | | Filing Date May 19, 2004 | Group Art Unit 1632 1633 |

Other Documents (include Author, Title, Date, and Place of Publication)

| Examiner Initial | Desig. ID | Document |
|---------------------|--------------|--|
| MK | FJ. | Sivanandham et al., "Colon cancer cell vaccine prepared with replication-deficient vaccinia viruses encoding B7.1 and interleukin-2 induce antitumor response in syngeneic mice," <i>Cancer Immunol Immunother</i> 46(5):261-7 (1998) |
| | FK. | Smyth et al., "Bovine enterovirus as an oncolytic virus: foetal calf serum facilitates its infection of human cells," <i>Int J Mol Med</i> 10(1):49-53 (2002) |
| | FL. | Soby et al., "Catabolite-repressor-like protein regulates the expression of a gene under the control of the <i>Escherichia coli</i> lac promoter in the plant pathogen <i>Xanthomonas campestris</i> pv. <i>Campestris</i> ," <i>Appl Microbiol Biotechnol</i> 46(5-6):559-61 (1996) |
| | FM. | Spooner et al., "In suicide gene therapy, the site of subcellular localization of the activating enzyme is more important than the rate at which it activates prodrug," <i>Cancer Gene Ther</i> 7(10):1348-56 (2000) |
| | FN. | Steffens et al., "Enhanced green fluorescent protein fusion proteins of herpes simplex virus type 1 thymidine kinase and cytochrome P450 4B1: applications for prodrug-activating gene therapy," <i>Cancer Gene Ther</i> 7(5):806-12 (2000) |
| | FO. | Tanaka et al., "Preliminary evaluation of intratumoral injection of a <i>Streptococcus pyogenes</i> preparation in patients with malignant brain tumors," <i>Cancer</i> 46(7):1688-94 (1980) |
| | FP. | Tartaglia et al., "NYVAC: a highly attenuated strain of vaccinia virus," <i>Virology</i> 188(1):217-32 (1992) |
| | FQ. | Thatcher et al., "The potential of acetaminophen as a prodrug in gene-directed enzyme prodrug therapy," <i>Cancer Gene Ther</i> 7(4):521-5 (2000) |
| | FR. | Theys et al., "Specific targeting of cytosine deaminase to solid tumors by engineered <i>Clostridium acetobutylicum</i> ," <i>Cancer Gene Ther</i> 8(4):294-7 (2001) |
| | FS. | Theys et al., "Stable <i>Escherichia coli</i> - <i>Clostridium acetobutylicum</i> shuttle vector for secretion of murine tumor necrosis factor alpha," <i>Appl Environ Microbiol</i> 65(10):4295-4300 (1999) |
| | FT. | Tietze et al., "Highly selective glycosylated prodrugs of cytostatic CC-1065 analogues for antibody-directed enzyme tumor therapy," <i>ChemBiochem</i> 2(10):758-65 (2001) |
| | FU. | Timiryasova et al., "Radiation enhances the anti-tumor effects of vaccinia-p53 gene therapy in glioma," <i>Technol Cancer Res Treat</i> 2(3):223-35 (2003) |
| | FV. | Toso et al., "Phase I study of the intravenous administration of attenuated <i>Salmonella typhimurium</i> to patients with metastatic melanoma," <i>J Clin Oncol</i> 20(1):142-52 (2002) |
| | FW. | Ullrich C.I. and R. Aloni, "Vascularization is a general requirement for growth of plant and animal tumours," <i>Journal of Experimental Botany</i> 51(353):1951-60 (2000). |
| | FX. | Webley et al., "Measurement of the critical DNA lesions produced by antibody-directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material," <i>Br J Cancer</i> 84(12):1671-6 (2001) |
| | FY. | Weedon et al., "Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression of <i>E. coli</i> nitroreductase," <i>Int J Cancer</i> 86(6):848-54 (2000) |
| | FZ. | Wehl et al., "Trends in infection morbidity in a pediatric oncology ward, 1986-1995," <i>Med Pediatr Oncol</i> 32(5):336-43 (1999) |
| MK | GA. | Westphal et al., "The nitroreductase/CB1954 combination in Epstein-Barr virus-positive B-cell lines: induction of bystander killing in vitro and in vivo," <i>Cancer Gene Ther</i> 7(1):97-106 (2000) |

| | |
|---|---------------------------|
| Examiner Signature  | Date Considered 6/2/06 |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609/Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

| | | | | | |
|---|--------------|--|--|---|-------------------------------|
| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | | Attorney's Docket No. 17248-004002/4804B | Application No. 10/849,664 |
| List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | | | | Applicant Szalay et al. | |
| | | | | Filing Date May 19, 2004 | Group Art Unit 1632-1633 |
| Other Documents (include Author, Title, Date, and Place of Publication) | | | | | |
| Examiner Initial | Desig. ID | Document | | | |
| PMK | GB. | Wollowski et al., "Protective role of probiotics and prebiotics in colon cancer," Am J Clin Nutr. 73 (2 Suppl):451S-455S (2001) | | | |
| | GC. | Wu et al., "Biological purging of breast cancer cells using an attenuated replication-competent herpes simplex virus in human hematopoietic stem cell transplantation," Cancer Res. 61(7):3009-15 (2001) | | | |
| | GD. | Yamamoto et al., "Production of L-forms of <i>Streptococcus pyogenes</i> and their antitumor effects," Jpn J Exp Med. 50(5):383-8 (1980) | | | |
| | GE. | Yazawa et al., " <i>Bifidobacterium longum</i> as a delivery system for cancer gene therapy: Selective localization and growth in hypoxic tumors," Cancer Gene Ther. 7(2):269-74 (2000) | | | |
| | GF. | Yazawa et al., " <i>Bifidobacterium longum</i> as a delivery system for gene therapy of chemically induced rat mammary tumors. Breast Cancer Res Treat. 66(2):165-70 (2001) | | | |
| | GG. | Yu et al., "Visualization of tumors and metastases in live animals with bacteria and vaccinia virus encoding light-emitting proteins," Nature Biotechnology 22(3):313-320 (2004) | | | |
| | GH. | Zambryski et al., "Tumor induction by <i>Agrobacterium tumefaciens</i> : analysis of the boundaries of T-DNA," J Mol Appl Genet. 1(4):361-70 (1982) | | | |
| | GI. | Zheng et al., "Tumor amplified protein expression therapy: <i>Salmonella</i> as a tumor-selective protein delivery vector," Oncology Research 12(3):127-135 (2000) | | | |
| PMK | GJ. | zur Hausen, H., "Papillomaviruses and cancer: from basic studies to clinical application. Nature Reviews Cancer 2(5):342-50 (2002) | | | |

| | |
|---|---------------------------|
| Examiner Signature  | Date Considered 6/2/06 |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

Sheet 1 of 9Substitute Form PTO-1449
(Modified)U.S. Department of Commerce
Patent and Trademark OfficeAttorney's Docket No.
17248-004002/ 4804BApplication No.
10/849,664**List of Patents and Publications for Applicant's
Information Disclosure Statement**Applicant
Aladar Szalay et al.Filing Date
May 19, 2004Group Art Unit
1632 1633

(37 CFR §1.98(b))

U.S. Patent Documents

| Examiner Initial | Desig. ID | Document Number | Publication Date | Patentee | Class | Subclass | Filing Date If Appropriate |
|------------------|-----------|-----------------|------------------|----------------------|-------|----------|----------------------------|
| 24K | AA | 2003/0009015 | 01/09/03 | Ulrich et al. | 536 | 23.1 | 06/25/97 |
| | AB | 2003/0031681 | 02/13/03 | Mc Cart et al. | 424 | 186.1 | 11/13/01 |
| | AC | 2003/0086906 | 05/08/03 | Mastrangelo et al. | 424 | 93.2 | 11/04/02 |
| | AD | 2003/0165465 | 09/04/03 | Roberts et al. | 424 | 93.2 | 06/13/02 |
| | AE | 2003/0198627 | 10/23/03 | Arts et al. | 424 | 93.21 | 08/23/02 |
| | AF | 2003/0228330 | 12/11/03 | Falkner et al. | 424 | 232.1 | 03/14/03 |
| | AG | 4,722,848 | 02/02/88 | Paoletti et al. | 424 | 199.1 | 06/19/84 |
| | AH | 5,693,533 | 12/02/97 | Raney et al. | 435 | 366 | 12/07/94 |
| | AI | 5,718,902 | 02/17/98 | Yilma et al. | 424 | 211.1 | 06/17/91 |
| | AJ | 5,830,702 | 11/03/98 | Portnoy et al. | 435 | 69.3 | 12/30/94 |
| | AK | 6,093,700 | 07/25/00 | Mastrangelo et al. | 514 | 44 | 02/20/97 |
| | AL | 6,190,657 | 02/20/01 | Pawelek et al. | 424 | 93.1 | 06/04/96 |
| | AM | 6,428,968 | 08/06/02 | Molnar-Kimber et al. | 435 | 7.23 | 11/08/99 |
| | AN | 6,455,673 | 09/24/02 | Collier | 530 | 350 | 02/16/99 |
| | AO | 6,548,068 | 04/15/03 | Schlom et al. | 424 | 199.1 | 01/07/00 |
| | AP | 6,596,279 | 07/22/03 | Paoletti et al. | 424 | 199.1 | 08/14/98 |
| | AQ | 6,627,160 | 09/03/03 | Wold et al. | 424 | 93.2 | 09/19/01 |
| 24K | AR | 6,685,935 | 02/03/04 | Pawelek et al. | 424 | 93.2 | 07/21/99 |

Foreign Patent Documents or Published Foreign Patent Applications

| Examiner Initial | Desig. ID | Document Number | Publication Date | Country or Patent Office | Class | Subclass | Translation | |
|------------------|-----------|-----------------|------------------|--------------------------|-------|----------|-------------|----|
| | | | | | | | Yes | No |
| 24K | AS | 0 037 441 | 10/14/81 | EP, A1 | | | | |
| | AT | 0 037 441 | 05/09/84 | EP, B1 | | | | |
| | AU | 03/045153 | 06/05/03 | PCT A1 | | | | |
| | AV | 03/102168 | 12/11/03 | PCT A1 | | | | |
| | AW | 1 281 777 | 02/05/03 | EP A1 | | | | |
| 24K | AX | 99/32646 | 07/01/99 | PCT | | | | |

Examiner Signature

Robert A. Kelly

Date Considered

6/2/06

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


OIP E

FEB 17 2005

Sheet 2 of 9

| | | | |
|---|--|--|-------------------------------|
| Substitute Form PTO-449 (Modified) List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 17248-004002/ 4804B | Application No. 10/849,664 |
| | Applicant Aladar Szalay et al. | | |
| | Filing Date May 19, 2004 | Group Art Unit 1632 1633 | |

| Other Documents (include Author, Title, Date, and Place of Publication) | | |
|---|-----------|--|
| Examiner Initial | Desig. ID | Document |
| ZMK | AY | "Generation of Recombinant Vaccinia Viruses," Unit 16.17 in <i>Short Protocols in Molecular Biology 2nd edition: a compendium of Methods from Current Protocols in Molecular Biology</i> , Green Publishing and Wiley-Interscience Supplement 15:16.71-16.82 (1992) |
| | AZ | Adonai <i>et al.</i> , "Ex vivo cell labeling with ⁶⁴ Cu-pyruvaldehyde-bis(N ⁴ -methylthiosemicarbazone) for imaging cell trafficking in mice with positron-emission tomography," <i>Proc. Natl. Acad. Sci. USA</i> 99: 3030-3035 (2002) |
| | BA | Altschul <i>et al.</i> , "Basic local alignment search tool," <i>J Molec Biol</i> 215:403-410 (1990) |
| | BB | Ando, N. and M. Matumoto, "Unmasking of growth of dermovaccinia strain dairen I in L cells by acid treatment of cells after virus adsorption," <i>Japan. J. Microbiol.</i> 14(3): 181-186 (1979) |
| | BC | Antoine <i>et al.</i> , "The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses," <i>Virology</i> 244: 365-396 (1998) |
| | BD | ATCC Accession No. 59324 |
| | BE | ATCC Accession No. 59325 |
| | BF | ATCC Accession Nos. CCL-121 |
| | BG | ATCC Accession Nos. CRL-12011 |
| | BH | ATCC Accession Nos. CRL-12012 |
| | BI | ATCC catalog no. 700294 |
| | BJ | ATCC No. CCL-107 |
| | BK | ATCC No. CRL-6475 |
| | BL | ATCC under Accession number: VR-1549 |
| | BM | Barrett <i>et al.</i> , "Yellow Fever Vaccines," <i>Biologicals</i> 25:17-25 (1997) |
| | BN | Bauerschnitz <i>et al.</i> , "Treatment of Ovarian Cancer with a Tropism Modified Oncolytic Adenovirus," <i>Cancer Research</i> 62: 1266-1270 (2002) |
| | BO | Benes <i>et al.</i> , "M13 and pUC vectors with new unique restriction sites for cloning," <i>Gene</i> 130: 151-152 (1993) |
| | BP | Bernards <i>et al.</i> , "Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector," <i>Proc. Natl. Acad. Sci. USA</i> 84: 6854-6858 (1987) |
| | BQ | Beshara <i>et al.</i> , "Kinetic analysis of ⁵² Fe-labelled iron(III) hydroxide-sucrose complex following blous administration using positron emission tomography," <i>Br. J. Haematol.</i> 104: 288-295 (1999) |
| | BR | Beshara <i>et al.</i> , "Pharmacokinetics and red cell utilization of iron(III) hydroxide-sucrose complex in anaemic patients: a study using positron emission tomography," <i>Br. J. Haematol.</i> 104: 296-302 (1999) |
| | BS | Bisno <i>et al.</i> , "Streptococcal infections of skin and soft tissues," <i>N. Engl. J. Med.</i> 334(4): 240-245 (1996) |
| ZMK | BT | Blakemore, "Magnetotactic Bacteria," <i>Annu. Rev. Microbiol.</i> 36: 217-238 (1982) |


| | |
|---|---------------------------|
| Examiner Signature  | Date Considered 6/2/06 |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 17248-004002/ 4804B | Application No. 10/849,664 |
|---|--------------|---|--|-------------------------------|
| List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | | | Applicant AJadar Szalay et al. | |
| | | | Filing Date May 19, 2004 | Group Art Unit 1632 / 633 |
| Other Documents (include Author, Title, Date, and Place of Publication) | | | | |
| Examiner Initial | Desig. ID | Document | | |
| RMK | BU | Broder, C.C. and P.L. Earl, "Recombinant Vaccinia Viruses," Mol. Biotechnol. 13: 223-245 (1999) | | |
| | BV | Brouqui, P. and D. Raoult, "Endocarditis due to rare and fastidious bacteria," Clinical Microbiology Reviews 14(1): 177-207 (2001) | | |
| | BW | Calonder <i>et al.</i> , "Kinetic modeling of $^{52}\text{Fe}/^{52}\text{Mn}$ -Citrate at the Blood-Brain Barrier by Positron Emission Tomography," J. Neurochem. 73: 2047-2055 (1999) | | |
| | BX | Carrillo and Lipman <i>et al.</i> , "The Multiple Sequence Alignment Problem in Biology," SIAM J Applied Math 48:1073-1082 (1988) | | |
| | BY | Chakrabarti <i>et al.</i> , "Vaccinia virus expression vector: coexpression of β -galactosidase provides visual screening of recombinant virus plaques," Mol. Cell Biol. 5:3403-3409 (1985) | | |
| | BZ | Chakrabarti <i>et al.</i> , "Compact, Synthetic, Vaccinia Virus Early/Late Promoter for Protein Expression," BioTechniques 23(6): 1094-1097 (1997) | | |
| | CA | Chamberlain <i>et al.</i> , "Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines," Cancer Res. 56: 2832-2836 (1996) | | |
| | CB | Child <i>et al.</i> , "Insertional inactivation of the large subunit of ribonucleotide reductase encoded by vaccinia virus is associated with reduced virulence <i>in vivo</i> ," Virology 174:625-629 (1990) | | |
| | CC | Colinas <i>et al.</i> , "A DNA ligase gene in the copenhagen strain of vaccinia virus is nonessential for viral replication and recombination," Virology 179: 267-275 (1990) | | |
| | CD | Cusumano <i>et al.</i> , "Synergic activities of streptococcal pyrogenic exotoxin A and lipoteichoic acid in cytokine induction," Microbiologica 23(1): 37-45 (2000) | | |
| | CE | Davison, A. J. and B. Moss, "Structure of Vaccinia Virus Early Promoters," J. Mol. Biol. 210: 749-769 (1989) | | |
| | CF | Davison <i>et al.</i> , "New vaccinia virus recombination plasmids incorporating a synthetic late promoter for high level expression of foreign proteins," Nucleic Acids Research 18: 4285-4286 (1990) | | |
| | CG | Devereux, J., <i>et al.</i> , "A comprehensive set of sequence analysis programs for the VAX," Nucleic Acids Research 12(1): 387-95 (1984) | | |
| | CH | Earl <i>et al.</i> , "T-Lymphocyte Priming and Protection Against Friend Leukemia by Vaccinia-Retrovirus <i>env</i> Gene Recombinant," Science 234: 728-731 (1986) | | |
| | CI | Ebert <i>et al.</i> , "Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats," Cancer Research 63: 3605-3611 (2003) | | |
| | CJ | Ebert <i>et al.</i> , "Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer," Cancer Research 64: 3265-3270 (2004) | | |
| | CK | Estin <i>et al.</i> , "Recombinant vaccinia virus vaccine against the human melanoma antigen p97 for use in immunotherapy," Proc. Natl. Acad. Sci. USA 85: 1052-1056 (1988) | | |
| | CL | Ferretti <i>et al.</i> , "Complete genome sequence of an M1 strain of <i>Streptococcus pyogenes</i> ," Proc. Natl. Acad. Sci. USA 98(8): 4658-4663 (2001) | | |
| | CM | Flexner <i>et al.</i> , "Successful vaccination with a polyvalent live vector despite existing immunity to an expressed antigen," Nature 355:259-262 (1988) | | |
| | CN | Flexner <i>et al.</i> , "Characterization of Human Immunodeficiency Virus <i>gag/pol</i> Gene Products Expressed by Recombinant Vaccinia Viruses," Virology 166: 339-349 (1988) | | |
| | CO | Giedlin <i>et al.</i> , "Vesicular stomatitis virus: an exciting new therapeutic oncolytic virus candidate for cancer or just another chapter from <i>Field's Virology</i> ?" Cancer Cell 4: 241-243 (2003) | | |
| RMK | CP | Goebel <i>et al.</i> , "The complete DNA sequence of vaccinia virus," Virology 179:247-266 (1990) | | |
| Examiner Signature <i>Rand J. Kelly</i> | | Date Considered 6/2/06 | | |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | |


| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | | Attorney's Docket No. 17248-004002/ 4804B | Application No. 10/849,664 |
|---|--------------|--|--|--|-------------------------------|
| List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | | | | Applicant Aladar Szalay et al. | |
| | | | | Filing Date May 19, 2004 | Group Art Unit 1632 1633 |
| Other Documents (include Author, Title, Date, and Place of Publication) | | | | | |
| Examiner Initial | Desig. ID | Document | | | |
| ZUK | CQ | Goebel et al., "Appendix to 'The complete DNA Sequence of Vaccinia Virus,'" Virology 179: 517-563 (1990) | | | |
| | CR | Green et al., "Necrotizing Fasciitis," Chest 110(1):219-229 (1996) | | | |
| | CS | Greinwald et al., "Treatment of lymphangiomas in children: an update of Picibanil (Ok-432) sclerotherapy," Otolaryngol Head Neck Surg 121(4): 381-387 (1999) | | | |
| | CT | Gribskov et al., "Sigma factors from E. coli, B. subtilis, phage SP01, and phage T4 are homologous proteins," Nucl. Acids Res. 14:6745-6763 (1986) | | | |
| | CU | Huang et al., "Oncolysis of hepatic metastasis of colorectal cancer by recombinant vesicular stomatitis virus in immune-competent mice," Mol. Ther. 8(3): 434-440 (2003) | | | |
| | CV | Hurst et al., "A novel model of a metastatic human breast tumour xenograft line," Br. J. Cancer 68: 274-276 (1993) | | | |
| | CW | Isaacs et al., "Vaccinia virus complement-control protein prevents antibody-dependent complement-enhanced neutralization of infectivity and contributes to virulence," Proc Natl Acad Sci U S A. 89:628-632 (1992) | | | |
| | CX | Johnson et al., "An update on the vaccinia virus genome," Virology 196: 381-401 (1993) | | | |
| | CY | Kantor et al., "Antitumor Activity and Immune Responses Induced by a Recombinant Carcinoembryonic Antigen-Vaccinia Virus Vaccine," J. Natl. Cancer Inst. 84: 1084-1091 (1992) | | | |
| | CZ | Katz et al., "Mutations in the vaccinia virus A33R and B5R envelope proteins that enhance release of extracellular virions and eliminate formation of actin-containing microvilli without preventing tyrosine phosphorylation of the A36R protein," J. Virology 77:12266-12275 (2003) | | | |
| | DA | Kotwal et al., "Mapping and Insertional Mutagenesis of a Vaccinia Virus Gene Encoding a 13, 800-Da Secreted Protein," Virology 171:579-587 (1989) | | | |
| | DB | Kozak, M., "Structural features in Eukaryotic mRNAs that modulate the Initiation of Translation," J. Biol. Chem. 266:19867-19870 (1991) | | | |
| | DC | Lamberton et al., "Construction and characterization of a bioluminescent <i>Streptococcus pyogenes</i> ," Proceedings of the 12th International Symposium on Bioluminescence and Chemiluminescence "Progress & Current Applications, Stanley, P.E. and L.J. Kricka et al (Eds). World Scientific Publishing Co. Pte. Ltd., pp 85-88 (2002) | | | |
| | DD | Lamberton et al., "Generation and characterization of a bioluminescent <i>Streptococcus pyogenes</i> ," Proceedings of the 12th International Symposium on Bioluminescence & Chemiluminescence: 5-9 April 2002, Robinson College, University of Cambridge, UK, p 3.22 (2002) | | | |
| | DE | Lathe et al., "Tumour prevention and rejection with recombinant vaccinia," Nature (London) 326: 878-880 (1987) | | | |
| | DF | Lee et al. "Prodrug and antedrug: two diametrical approaches in designing safer drugs," Arch. Pharm. Res. 25(2): 111-136 (2002) | | | |
| | DG | Lee et al., "Molecular attenuation of vaccinia virus: mutant generation and animal characterization," Journal of Virology 66:2617-2630 (1992) | | | |
| ✓ | DH | Leenders et al., "Blood to brain iron uptake in one Rhesus monkey using [Fe-52]-citrate and positron emission tomography (PET): influence of haloperidol," J. Neural Transm. Suppl. 43: 123-132 (1994) | | | |
| ZUK | DI | Lemmon et al., "Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment," Gene Therapy 4: 791-796 (1997) | | | |
| Examiner Signature | | Date Considered | | | |
| [Signature] | | 6/2/06 | | | |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | |

| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 17248-004002/ 4804B | Application No. 10/849,664 |
|---|--------------|--|--|-------------------------------|
| List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | | | Applicant Aladar Szalay et al. | |
| | | | Filing Date May 19, 2004 | Group Art Unit 1632-1633 |
| Other Documents (include Author, Title, Date, and Place of Publication) | | | | |
| Examiner Initial | Desig. ID | Document | | |
| MK | DJ | Lemmon et al., "Anaerobic bacteria as a gene delivery system to tumors," Proceedings of the 85th Annual Meeting of the American Association for Cancer Research, San Francisco, CA April 10-13, 1994, published in: Proc. Am. Cancer Research Assn 35: 374 (1994) | | |
| | DK | Lewis et al., "Comparison of Four ⁶⁴ Cu-Labeled Somatostatin Analogues in Vitro and in a Tumor-Bearing Rat Model: Evaluation of New Derivatives for Positron Emission Tomography Imaging and Targeted Radiotherapy," J. Med. Chem. 42: 1341-1347 (1999) | | |
| | DL | Li et al., "Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy: Selective Inhibitor of angiogenesis and hypoxic tumor growth," Cancer Gene Therapy 10: 105-111 (2003) | | |
| | DM | Liau et al., "Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens," J. Neurosurg. 90(6): 1115-1124 (1999) | | |
| | DN | Liu et al., "An E1B-19 kDa gene deletion mutant adenovirus demonstrates tumor necrosis factor-enhanced cancer selectivity and enhanced oncolytic potency," Molecular Therapy 9(6): 786-803 (2004) | | |
| | DO | Lopez et al., "Infections in children with malignant disease in Argentina," Cancer 47(5): 1023-1030 (1981) | | |
| | DP | Mayford et al., "CaMKII Regulates the Frequency-Response Function of Hippocampal Synapses for the Production of Both LTD and LTP," Cell 81: 891-904 (1995) | | |
| | DQ | Mayr et al., "The Smallpox Vaccination Strain MVA: Marker, Genetic Structure, Experience Gained with the Parenteral Vaccination and Behavior in Organisms with a Debilitated Defense Mechanism," Zentbl. Bakteri. Hyg. Abt. 1 Orig. B 167: 375-390 (1978) [In German, English abstract on first page of article] | | |
| | DR | McAllister et al., "Recombinant yellow fever viruses are effective therapeutic vaccines for treatment of murine experimental solid tumors and pulmonary metastases," J. Virol. 74:9197-9205 (2000). | | |
| | DS | McAneny et al., "Results of a Phase I trial of a recombinant vaccinia virus that expresses carcinoembryonic antigen in patients with advanced colorectal cancer," Ann. Surg. Oncol. 3(5): 495-500 (1996) | | |
| | DT | Mikryukov et al., "Structural-functional organization of segment of vaccinia virus genome," Soviet Biotechnology (Biotekhnologiya) 4: 19-25 (1988) [corresponds to pages 442-449 in the Russian language edition] | | |
| | DU | Moore et al., "Steroid hormone synthesis by a vaccinia enzyme: a new type of virus virulence factor," EMBO J. 1992 11:1973-1980, corrigendum in The EMBO Journal 11(9): 3490 (1992) | | |
| | DV | Moss, B., "Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety," Proc. Natl. Acad. Sci. USA 93: 11341-11348 (1996) | | |
| | DW | Moss, B., "Poxvirus vectors: cytoplasmic expression of transferred genes," Curr. Opin. Genet. Dev. 3: 86-90 (1993) | | |
| | DX | Mullen et al., "Viral Oncolysis," The Oncologist 7: 106-119 (2002) | | |
| | DY | Mulryan et al., "Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors," Mol Cancer Ther 1(12): 1129-1137 (2002) | | |
| MK | DZ | Munagala et al., "The purine nucleoside phosphorylase from Trichomonas vaginalis is a homologue of the bacterial enzyme," Biochemistry 41(33): 10382-10389 (2002) | | |
| Examiner Signature <i>Robert J. Kelly</i> | | Date Considered 6/2/06 | | |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | |


| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 17248-004002/ 4804B | Application No. 10/849,664 |
|---|---|---|--|-------------------------------|
| List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | | | Applicant Aladar Szalay et al. | |
| | | | Filing Date May 19, 2004 | Group Art Unit 1632 1633 |
| Other Documents (include Author, Title, Date, and Place of Publication) | | | | |
| Examiner Initial | Desig. ID | Document | | |
| ZUK | EA | NCBI Protein AAA48282 | | |
| | EB | NCBI Nucleotide AF012825 | | |
| | EC | NCBI Nucleotide. AF095689 | | |
| | ED | NCBI Nucleotide AF380138 | | |
| | EE | NCBI Nucleotide AX003206 | | |
| | EF | NCBI Nucleotide. AY009089 | | |
| | EG | NCBI Nucleotide AY243312 | | |
| | EH | NCBI Nucleotide AY484669 | | |
| | EI | NCBI Nucleotide AY603355 | | |
| | EJ | NCBI Nucleotide M35027 | | |
| | EK | NCBI Nucleotide M57977 | | |
| | EL | NCBI Nucleotide U94848 | | |
| | EM | NCBI Nucleotide X69198 | | |
| | EN | NCBI Nucleotide X94355 | | |
| | EO | Needleman <i>et al.</i> , "A general method applicable to the search for similarities in the amino acid sequences of two proteins," J. Mol. Biol. 48:443-453 (1970) | | |
| | EP | Nogrady, T., <i>Medicinal Chemistry A Biochemical Approach</i> , New York: Oxford University Press, pages 388-392 (1985) | | |
| | EQ | Oertli <i>et al.</i> , "Non-replicating recombinant vaccinia virus encoding murine B-7 molecules effective costimulation of naive CD4 ⁺ splenocytes <i>in vitro</i> ," J. Gen. Virol. 77: 3121-3125 (1996) | | |
| | ER | Okamoto <i>et al.</i> , "Severe impairment of anti-cancer effect of lipoteichoic acid-related molecule isolated from a penicillin-killed <i>Streptococcus pyogenes</i> in toll-like receptor 4-deficient mice," International Immunopharmacology 1(9-10): 1789-1795 (2001) | | |
| | ES | Patel <i>et al.</i> , "A poxvirus-derived vector that directs high levels of expression of cloned genes in mammalian cells," Proc. Natl. Acad. Sci. USA 85: 9431-9435 (1988) | | |
| | ET | Pawelek <i>et al.</i> , "Tumor-targeted <i>Salmonella</i> as a Novel Anticancer Vector," Cancer Therapy 57: 4537-4544 (1997) | | |
| EU | Pearson <i>et al.</i> , "Improved tools for biological sequence comparison," Proc. Natl. Acad. Sci. USA 85:2444-2448 (1988) | | | |
| ↓ | EV | Pilcher, H., "GM Bug activates cancer drug: Bacteria targets medicine to shrivel mouse tumours," news @ nature.com, Published online: 22 April 2004; http://www.nature.com/news/2004/040419/full/040419-9.html , (accessed on November 18, 2004) | | |
| ZUK | EW | Pinkert <i>et al.</i> , "An albumin enhancer located 10 kb upstream functions along with its promoter to direct efficient, liver-specific expression in transgenic mice," Genes & Dev. 1: 268-76 (1987) | | |

| | |
|--|---------------------------|
| Examiner Signature  | Date Considered 6/2/06 |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | | Attorney's Docket No. 17248-004002/ 4804B | Application No. 10/849,664 |
|---|---|--|--|--|--|
| List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | | | | Applicant Aladar Szalay et al. | |
| | | | | Filing Date May 19, 2004 | Group Art Unit 1632 1633 |
| Other Documents (include Author, Title, Date, and Place of Publication) | | | | | |
| Examiner Initial | Desig. ID | Document | | | |
| ZMK | EX | Plucienniczak et al., "Nucleotide sequence of a cluster and late genes in a conserved segment of the vaccinia virus genome," Nucleic Acids Research 13(3): 993-998 (1985) | | | |
| | EY | Puhlmann et al., "Vaccinia virus as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant," Cancer Gene Therapy 7(1): 66-73 (2000) | | | |
| | EZ | Qin, H. and S.K. Chatterjee, "Cancer gene therapy using tumor cells infected with recombinant vaccinia virus expressing GM-CSF," Human Gene Ther. 7: 1853-1860 (1996) | | | |
| | FA | Rao et al., "IL-12 is an effective adjuvant to recombinant vaccinia virus-based tumor vaccines," J. Immunol. 156: 3357-3365 (1996) | | | |
| | FB | Rodriguez et al., "Highly attenuated vaccinia virus mutants for the generation of safe recombinant viruses," Proc. Natl. Acad. Sci. USA 86: 1287-1291 (1989) | | | |
| | FC | Rolston et al., "In vitro activity of LY264826, a new glycopeptide antibiotic, against gram-positive bacteria isolated from patients in cancer," Antimicrob. Agents Chemother. 34(11):2137-2141 (1990) | | | |
| | FD | Roseman et al., "The vaccinia virus HindIII fragment: nucleotide sequence of the left 6.2kb," Virology 178: 410-418 (1990) | | | |
| | FE | Roth et al., "p53 as a target for cancer vaccines: recombinant canarypox virus vectors expressing p53 protect mice against lethal tumor cell challenge," Proc. Natl. Acad. Sci. USA 93: 4781-4786 (1996) | | | |
| | FF | Schwartz and Dayhoff, eds., ATLAS OF PROTEIN SEQUENCE AND STRUCTURE, National Biomedical Research Foundation, pp. 353-358 (1979) | | | |
| | FG | Shilo, B. and R.A. Weinberg, "DNA sequences homologous to vertebrate oncogenes are conserved in Drosophila melanogaster," Proc. Natl. Acad. Sci. USA 78:6789-6792 (1981) | | | |
| | FH | Shinozaki et al., "Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus," Mol. Ther. 9(3): 368-376 (2004) | | | |
| | FI | Silva et al., "Cloning, overexpression, and purification of functional human purine nucleoside phosphorylase," Protein Expr. Purif. 27(1): 158-164 (2003) | | | |
| | FJ | Smith, T.F. and M.S. Waterman, "Comparison of biosequences," Adv. Appl. Math. 2:482-489 (1981) | | | |
| | FK | Sorscher et al., "Tumor cell bystander killing in colonic carcinoma utilizing the Escherichia coli DeoD gene to generate toxic purines," Gene Therapy 1(4): 233-238 (1994) | | | |
| | FL | Stevens, D.L., "Streptococcal toxic-shock syndrome: spectrum of disease, pathogenesis, and new concepts in treatment," Emerg. Infect. Dis. 1(3): 69-78 (1995) | | | |
| | FM | Sugimoto, M. and K. Yamanouchi., "Characteristics of an attenuated vaccinia virus strain, LC16m0, and its recombinant virus vaccines," Vaccine 12(8): 675-681 (1994) | | | |
| FN | Sugimoto et al., "Gene structures of low-neurovirulent vaccinia virus LC16m0, LC16m8, and their Lister Original (LO) strains," Microbial. Immunol. 29: 421-428 (1985) | | | | |
| FO | Suvorov et al., "Physical and genetic chromosomal map of an M type 1 strain of Streptococcus pyogenes," J. Bacteriol. 178(18): 5546-5549 (1996) | | | | |
| FP | Suzuki et al., "Management of orbital lymphangioma using intralesional injection of OK-432," Br. J. Ophthalmol. 84(6): 614-617 (2000) | | | | |
| FQ | Sze et al., "Dr. Gary J. Becker Young Investigator Award: intraarterial adenovirus for metastatic gastrointestinal cancer: activity, radiographic response, and survival," J. Vasc. Interv. Radiol. 14(3): 279-290 (2003) | | | | |

| | |
|---|---------------------------|
| Examiner Signature  | Date Considered 6/2/06 |
| EXAMINER: Initial if citation considered; whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 17248-004002/ 4804B | Application No. 10/849,664 |
|---|--------------|--|--|-------------------------------|
| List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | | | Applicant Aladar Szalay et al. | |
| | | | Filing Date May 19, 2004 | Group Art Unit 1632-1633 |
| Other Documents (include Author, Title, Date, and Place of Publication) | | | | |
| Examiner Initial | Desig. ID | Document | | |
| PK | FR | Takahashi-Nishimaki <i>et al.</i> , "Genetic analysis of vaccinia virus Lister strain and its attenuated mutant LC16m8: production of intermediate variants by homologous recombination," J. Gen. Virol. 68: 2705-2710 (1987) | | |
| PK | FS | Theys <i>et al.</i> , "Tumor-specific gene delivery using genetically engineered bacteria," Curr Gene Ther 3(3): 207-221 (2003) | | |
| | ET | Timiryasova <i>et al.</i>, "[Analysis of reporter gene expression at different segments of the vaccinia virus genome]," Mol. Biol. (Mosk.) 27(2): 392-401 (1993) [article in Russian, English abstract on last page of article] | | |
| PK | FU | Timiryasova <i>et al.</i> , "Construction of recombinant vaccinia viruses using PUV-inactivated virus as a helper," BioTechniques 31: 534-540 (2001) | | |
| | FV | Toth <i>et al.</i> , "An oncolytic adenovirus vector combining enhanced cell-to-cell spreading, mediated by the ADP cytolytic protein, with selective replication in cancer cells with deregulated <i>Wnt</i> signaling," Cancer Research 64: 3638-3644 (2004) | | |
| | FW | Tsung <i>et al.</i> , "Gene expression and cytopathic effect of vaccinia virus inactivated by psoralen and long-wave UV light," J. Virol. 70: 165-171 (1996) | | |
| | FX | Umphress <i>et al.</i> , "Vaccinia virus mediated expression of human APC induces apoptosis in colon cancer cells," Transgenics 4:19-33 (2003) | | |
| | FY | Veijola <i>et al.</i> , "Cloning, Baculovirus Expression, and Characterization of the α Subunit of Prolyl 4-Hydroxylase from the nematode <i>Caenorhabditis elegans</i> ," J. Biol. Chem. 269: 26746-26753 (1994) | | |
| | FZ | Vidal <i>et al.</i> , "Tissue-specific control elements of the Thy-1 gene," EMBO J. 9(3): 833-840 (1990) | | |
| | GA | Watson <i>et al.</i> Molecular Biology of the Gene, 4th Edition, 1987, The Benjamin/Cummings Pub. co., p.224 | | |
| | GB | Wolffe <i>et al.</i> , "Deletion of the vaccinia virus B5R gene encoding a 42-kilodalton membrane glycoprotein inhibits extracellular virus envelope formation and dissemination," Journal of Virology 67(8): 4732-4741 (1993) and erratum in Journal of Virology, vol. 67, pp5709-5711 (1993) | | |
| | GC | Wu <i>et al.</i> , "High resolution microPET imaging of carcino-embryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment," PNAS USA 97(15): 8495-8500 (2000) | | |
| | GD | Yang <i>et al.</i> , "Whole-body optical imaging of green fluorescent protein-expressing tumors and metastases," Proc. Natl. Acad. Sci. USA 97(3):1206-1211 (2000) | | |
| | GE | Yang <i>et al.</i> , "Effects of growth medium composition, iron sources and atmospheric oxygen concentrations on production of luciferase-bacterial magnetic particle complex by a recombinant <i>Magnetospirillum magneticum</i> AMB-1," Enzyme Microb. Technol. 29: 13-19 (2001) | | |
| | GF | Yazawa <i>et al.</i> , "Current progress in suicide gene therapy for cancer," World J. Surg 26(7): 783-789 (2002) | | |
| | GG | Yoshida <i>et al.</i> , "Cell growth-inhibitory action of SAGP, an antitumor glycoprotein from <i>Streptococcus pyogenes</i> (Su strain)," Jpn. J. Pharmacol. 45(2): 143-147 (1987) | | |
| | GH | Yoshida <i>et al.</i> , "Characterization of a streptococcal antitumor glycoprotein (SAGP)," Life Sciences 62(12): 1043-1053 (1998) | | |
| PK | GI | Yoshida <i>et al.</i> , "Growth-inhibitory effect of streptococcal antitumor glycoprotein on human epidermoid carcinoma A431 cells: involvement of dephosphorylation of epidermal growth factor receptor," Cancer Research 61(16): 6151-6157 (2001) | | |

| | |
|---|---------------------------|
| Examiner Signature  | Date Considered 6/2/06 |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

| | | | | | |
|---|--------------|--|--|---|-------------------------------|
| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | | Attorney's Docket No. 17248-004002/ 4804B | Application No. 10/849,664 |
| List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | | | | Applicant Aladar Szalay et al. | |
| | | | | Filing Date May 19, 2004 | Group Art Unit 1632-1633 |
| | | | | Other Documents (include Author, Title, Date, and Place of Publication) | |
| Examiner Initial | Desig. ID | Document | | | |
| <i>PK</i> | GJ | Zimmermann <i>et al.</i> , "Independent regulatory elements in the nestin gene direct transgene expression to neural stem cells," <i>Neuron</i> 12: 11-24 (1994) | | | |
| <i>PK</i> | GK | Zolotukhin <i>et al.</i> , "A "Humanized" Green Fluorescent Protein cDNA adapted for high-level expression in mammalian cells," <i>J. Virol.</i> 70:4646-4654 (1996) | | | |

| | |
|---|----------------------------------|
| Examiner Signature <i>Robert A. Kelly</i> | Date Considered <i>6/2/06</i> |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |



Sheet 1 of 6

| | | | |
|---|--|---|-------------------------------|
| Substitute Form PTO-1449 (Modified) | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 17248-004002/4804B | Application No. 10/849,664 |
| List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | | Applicant Aladar A. Szalay et al. | |
| | | Filing Date May 19, 2004 | Group Art Unit 1632 1633 |

| Examiner Initial | Desig. ID | Document Number | Publication Date | Patentee | Class | Subclass | Filing Date If Appropriate |
|------------------|-----------|-----------------|------------------|-------------------------|-------|----------|----------------------------|
| PK | AA | 2002/0054865 | 05/09/02 | Fujimori et al. | 424 | 93.21 | 03/26/01 |
| | AB | 2003/0031628 | 02/13/03 | Zhao et al. | 424 | 9.6 | 07/09/02 |
| | AC | 2003/0044384 | 03/06/03 | Roberts et al. | 424 | 93.2 | 01/15/02 |
| | AD | 2003/0161788 | 08/28/03 | Zhao et al. | 424 | 9.6 | 12/31/02 |
| | AE | 2003/0165477 | 09/04/03 | Balloul et al. | 424 | 93.21 | 04/12/01 |
| | AF | 2004/0076622 | 04/22/04 | Studený et al. | 424 | 93.21 | 02/28/03 |
| | AG | 2005/0249670 | 11/10/95 | Szalay et al. | 424 | 9.32 | 06/27/05 |
| | AH | 2006/0051370 | 03/09/06 | Szalay et al. | 424 | 199.1 | 09/27/05 |
| | AI | 5,650,135 | 07/22/97 | Contag et al. | 424 | 9.1 | 07/01/94 |
| | AJ | 6,007,806 | 12/28/99 | Lathe et al. | 424 | 93.2 | 12/12/97 |
| | AK | 6,099,848 | 08/08/00 | Frankel et al. | 424 | 246.1 | 11/18/97 |
| | AL | 6,232,523 | 05/15/01 | Tan et al. | 800 | 10 | 04/28/97 |
| | AM | 6,235,967 | 05/22/01 | Tan et al. | 800 | 10 | 03/27/98 |
| | AN | 6,235,968 | 05/22/01 | Tan et al. | 800 | 10 | 04/28/98 |
| | AO | 6,251,384 | 06/26/01 | Tan et al. | 424 | 93.21 | 01/07/99 |
| | AP | 6,416,754 | 07/09/02 | Brown et al. | 424 | 93.21 | 07/23/96 |
| | AQ | 6,589,531 | 07/08/03 | Andino-Pavlovsky et al. | 424 | 199.1 | 09/01/00 |
| | AR | 6,627,190 | 09/30/03 | Wold et al. | 424 | 93.2 | 09/19/01 |
| | AS | 6,649,143 | 11/18/03 | Contag et al. | 424 | 9.1 | 01/19/99 |
| | AT | 6,649,159 | 11/18/03 | Yang et al. | 424 | 93.21 | 03/19/01 |
| | AU | 6,652,849 | 11/25/00 | Brown et al. | 424 | 93.2 | 05/17/02 |
| ↓ | AV | 6,759,038 | 06/06/04 | Tan et al. | 424 | 93.21 | 05/29/01 |
| PK | AW | 6,984,374 | 01/10/06 | Szalay et al. | 123 | 435 | 01/30/03 |

| Foreign Patent Documents or Published Foreign Patent Applications | | | | | | | | |
|---|-----------|-----------------|------------------|--------------------------|-------|----------|-------------|----|
| Examiner Initial | Desig. ID | Document Number | Publication Date | Country or Patent Office | Class | Subclass | Translation | |
| | | | | | | | Yes | No |
| PK | AX | 0 861 093 | 09/28/98 | EP | | | | |
| ↓ | AY | 1 146 125 | 10/17/01 | EP | | | | |
| PK | AZ | 1 254 250 | 03/23/05 | EP | | | | |

| | |
|--|---------------------------|
| Examiner Signature <i>RL A. Kelly</i> | Date Considered 6/2/06 |
|--|---------------------------|

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | | Attorney's Docket No. 17248-004002/4804B | | Application No. 10/849,664 | | |
|---|--------------|--|---------------------|---|-------|-------------------------------|-------------|----|
| List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | | | | Applicant Aladar A. Szalay et al. | | | | |
| | | | | Filing Date May 19, 2004 | | Group Art Unit 1632 1637 | | |
| Foreign Patent Documents or Published Foreign Patent Applications | | | | | | | | |
| Examiner Initial | Desig. ID | Document Number | Publication Date | Country or Patent Office | Class | Subclass | Translation | |
| | | | | | | | Yes | No |
| TK | BA | 2002097144 | 04/02/02 | JP | | | | X+ |
| | BB | 55035004 | 03/11/80 | JP | | | | X* |
| | BC | 01/12234 | 02/22/01 | PCT | | | | |
| | BD | 01/20989 / | 03/29/01 | PCT | | | | |
| | BE | 01/55444 | 08/02/01 | PCT | | | | |
| | BF | 03/006069 | 01/23/03 | PCT | | | | |
| | BG | 03/057007 | 07/17/03 | PCT | | | | |
| | BH | 03/092600 | 11/13/03 | PCT | | | | |
| | BI | 03/102169 | 12/11/03 | PCT | | | | |
| | BJ | 2004/044175 / | 05/27/04 | PCT | | | | |
| | BK | 2005/047458 | 05/26/05 | PCT | | | | |
| | BL | 2005/057488 | 06/23/05 | PCT | | | | |
| ✓ | BM | 2005/072622 | 08/11/05 | PCT | | | | |
| TK | BN | 97/18841 | 05/29/97 | PCT | | | | |

X+ = An English language equivalent is provided

X* = An English language Derwent abstract is provided

| Other Documents (include Author, Title, Date, and Place of Publication) | | |
|---|--------------|--|
| Examiner Initial | Desig. ID | Document |
| TK | BO | "WHO Collaborating Centre for Orthopoxvirus Diagnosis and Repository for Variola Virus Strains and DNA," VECTOR: Ministry of Public Health and Social Development of Russian Federation, State Research Center of Virology and Biotechnology http://www.vector.nsc.ru/DesktopDefault.aspx?lcid=9&tabid=294&tabindex=1 (accessed on 09/12/05) |
| | BP | "A New Way to Kill Cancer: SLU Research Shows Viruses can destroy lung, colon tumors," Science Daily: Your link to the latest research news http://www.sciencedaily.com/releases/2004/05/040517071951.htm (accessed on 05/17/04) |
| | BQ | Advani et al., "Replication-competent, Nonneuroinvasive Genetically Engineered Herpes Virus Is Highly Effective in the Treatment of Therapy-resistant Experimental Human Tumors," Cancer Research 59: 2055-2058 (1999) |
| ✓ | BR | Altenbrunn et al., "Scintigraphic Tumor Localization in Mice with Radioiodinated Anti-Clostridium Antibodies," Int. J. Nucl. Med. Biol. 8(1): 90-93 (1981) |
| TK | BS | Bennett et al., "Positron emission tomography imaging for herpes virus infection: Implications for oncolytic viral treatments of cancer," Nature Med 7(7): 859-863 (2001) |





| | |
|---|---------------------------|
| Examiner Signature <i>Robert A. Kelly</i> | Date Considered 6/2/06 |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |


| | | | | | |
|---|--------------|---|--|---|-------------------------------|
| Substituted Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | | Attorney's Docket No. 17248-004002/4804B | Application No. 10/849,664 |
| List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | | | | Applicant Aladar A. Szalay et al. | |
| | | | | Filing Date May 19, 2004 | Group Art Unit 1632 1633 |
| Other Documents (Include Author, Title, Date, and Place of Publication) | | | | | |
| Examiner Initial | Desig. ID | Document | | | |
| MK | BT | Berger, F. and S.S. Gambhir, "Recent advances in imaging endogenous or transferred gene expression utilizing radionuclide technologies in living subjects," Breast Cancer Research 3: 28-35 (2001) | | | |
| | BU | Blasberg, R.G. and J.G. Tjuvjev, "Herpes simplex virus thymidine kinase as a marker/reporter gene for PET imaging of gene therapy," Q J Nucl Med 43(2): 163-169 (1999) | | | |
| | BV | Boland et al., "Adenovirus-mediated Transfer of the Thyroid Sodium/Iodide Symporter Gene into Tumors for a Targeted Radiotherapy," Cancer Research 60: 3484-3492 (2000) | | | |
| | BW | Bonnekoh et al., "Adenoviral-Mediated Herpes Simplex Virus-Thymidine Kinase Gene Transfer <i>in Vivo</i> for Treatment of Experimental Human Melanoma," J. Invest. Dermatol. 106(6): 1163-1168 (1996) | | | |
| | BX | Brockstedt et al., "Development of Anti-tumor Immunity against a Non-immunogenic Mammary Carcinoma through <i>in Vivo</i> Somatic GM-CSF, IL-2, and HSVtk Combination Gene Therapy," Mol. Ther. 6(5): 627-636 (2002) | | | |
| | BY | Certified English translation of abstract for Aksac S., "[Antibody formation against <i>Agrobacterium tumefaciens</i> in patients with various cancers]," Turk Hij Tecr Biyol Derg. 34(1-2):48-51 (1974) [Article in Italian]. | | | |
| | BZ | Certified English translation of journal article for Al'tshtein [Altshteyn] et al., "[Isolation of a recombinant vaccinia virus based on the LIVP strain inducing the surface antigen of the hepatitis B virus]," Dokl Akad Nauk SSSR. 285(3):696-9 (1985) [Article in Russian]. | | | |
| | CA | Chen B et al., "Evaluation of Cytokine Toxicity Induced by Vaccinia Virus-mediated IL-2 and IL-2 Antitumor Immunotherapy," Cytokine (2001) 15(6):305-314. | | | |
| | CB | Chaudhuri et al., "Light-based imaging of green fluorescent protein-positive ovarian cancer xenografts during therapy," Gynecol. Oncol. 82(3): 581-589 (2001) | | | |
| | CC | Derwent English abstract for Japanese Patent Publication JP 55035004, published February 3, 1987, entitled, "Cellular immuno-potentiator - contg. Vaccinia attenuated virus showing no infectivity to man or rabbit and has lost humoral immunity," Derwent Accession Number: 2512008 | | | |
| | CD | Fabricius et al., "Quantitative investigations into the elimination of <i>in vitro</i> -obtained spores of the non-pathogenic <i>Clostridium butyricum</i> strain CNRZ 528, and their persistence in organs of different species following intravenous spore administration," Res. Microbiol. 144: 741-753 (1993) | | | |
| | CE | Francis et al., "Monitoring bioluminescent <i>staphylococcus aureus</i> infections in living mice using a novel <i>luxABCDE</i> construct," Infection and Immunity 68(6): 3594-3600 (2000) | | | |
| | CF | Gambhir et al., "Imaging transgene expression with radionuclide imaging technologies," Neoplasia 2(1-2): 118-138 (2000) | | | |
| | CG | Gnant et al., "Regional Versus Systemic Delivery of Recombinant Vaccinia Virus as Suicide Gene Therapy for Murine Liver Metastases," Annals of Surgery 230(3): 352-361 (1999) | | | |
| | CH | Gnant et al., "Sensitization of tumor necrosis factor α -resistant human melanoma by tumor-specific <i>in vivo</i> transfer of the gene encoding endothelial monocyte-activating polypeptide II using recombinant vaccinia virus," Cancer Research 59: 4668-4674 (1999) | | | |
| | CI | Hamblin et al., "Rapid control of wound infections by targeted photodynamic therapy monitored by <i>in vivo</i> bioluminescence imaging," Photochemistry and Photobiology 75(1): 51-57 (2002) | | | |
| | CJ | Hansen et al., "Assessment of GFP fluorescence in cells of <i>Streptococcus gordonii</i> under conditions of low pH and low oxygen concentration," Microbiology 147: 1383-1391 (2001) | | | |
| MK | CK | Hasegawa et al., " <i>In vivo</i> tumor delivery of the green fluorescent protein gene to report future occurrence of metastasis," Cancer Gene Therapy 7: 1336-1340 (2000) | | | |
| Examiner Signature | | Date Considered | | | |
| [Signature] | | 6/2/06 | | | |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | |

| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | | Attorney's Docket No. 17248-004002/4804B | Application No. 10/849,664 |
|---|--------------|--|--|---|-------------------------------|
| List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | | | | Applicant Aladar A. Szalay et al. | |
| | | | | Filing Date May 19, 2004 | Group Art Unit 16321633 |
| Other Documents (include Author, Title, Date, and Place of Publication) | | | | | |
| Examiner Initial | Desig. ID | Document | | | |
| <i>PK</i> | CL | Hatta, M., "Antitumor mechanisms of <i>Eubacterium lentum</i> and its components," Asian Pacific Journal of Allergy and Immunology 13: 129-137 (1995) | | | |
| | CM | Hiller et al., "Characterization of Intracellular and Extracellular Vaccinia Virus Variants: N ₁ -Isonicotinoyl-N ₂ -3-Methyl-4-Chlorobenzoylhydrazine Interferes with Cytoplasmic Virus Dissemination and Release," Journal of Virology 39(3): 903-913 (1981) | | | |
| | CN | Ivanaro et al., "Expression of TGF- β in attenuated <i>Salmonella typhimurium</i> : oral administration leads to the reduction of inflammation, IL-2 and IFN- γ , but enhancement of IL-10, in carrageenin-induced oedema in mice," Immunology 84:8-15 (1995) | | | |
| | CO | Jacobs et al., "Positron Emission Tomography-based Imaging of Transgene Expression Mediated by Replication-conditional, Oncolytic Herpes Simplex Virus Type I Mutant Vectors <i>in Vivo</i> ," Cancer Research 61: 2983-2995 (2001) | | | |
| | CP | Jain, R.K. and N.S. Forbes, "Can engineered bacteria help control cancer," Proc. Natl. Acad. Sci. USA 98(26): 14748-14750 (2001) | | | |
| | CQ | Joklik, W.K., "The Purification of Four Strains of Poxviruses," Virology 18:9-18 (1962) | | | |
| | CR | Kaplitt et al., "Mutant herpes simplex virus induced regression of tumors growing in immunocompetent rats," J. Neurooncol 19(2): 137-147 (1994) | | | |
| | CS | Kim, D.H. and F. McCormick, "Replicating viruses as selective cancer therapeutics," Mol Med Today 2(12): 519-527 (1996) | | | |
| | CT | Kutinova et al., "Search for optimal parent for recombinant vaccinia virus vaccines. Study of three vaccinia virus vaccinal strains and several virus lines derived from them," Vaccine 13(5): 487-493 (1995) | | | |
| | CU | Latime et al., "In Situ Cytokine Gene Transfection Using Vaccinia Virus Vectors," Semin Oncol 23(1): 88-100 (1996) | | | |
| | CV | Mackenzie et al., "Human mesenchymal stem cells persist, demonstrate site-specific multipotential differentiation, and are present in sites of wound healing and tissue regeneration after transplantation into fetal sheep," Blood Cells, Molecules, and Diseases 27(3): 601-604 (2001) | | | |
| | CW | Meyer et al., "Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence," Journal of General Virology 72(Pt 5): 1031-1038 (1991) | | | |
| | CX | Morinaga et al., "Antitumor activity and its properties of <i>Eubacterium lentum</i> ," Jpn. J. Cancer Res. (Gann) 79: 117-124 (1988) | | | |
| | CY | Muravlev et al., "Protective activity of vaccinia virus envelope proteins isolated with the use of nonionic detergents," Voprosy Virusologii 40(4): 154-8 (1995) [article in Russian, English summary on last page of article] | | | |
| | CZ | Netesova et al., "Structural and functional studies of the <i>Hind</i> III-I-Genome Fragment of Vaccinia virus Strain L-IVP," Mol Biol (Mosk.) Nov-Dec; 25(6): 1526-32 (1991) [article in Russian, English summary on last page of article] | | | |
| | DA | Norton et al., "Expression of Secreted Platelet-Derived Growth Factor-B by Recombinant Nonreplicating and Noncytopathic Vaccinia Virus," Annals of Surgery 224(4):555-562 (1996) | | | |
| | DB | Overwijk et al., "Vaccination with a recombinant vaccinia virus encoding a 'self' antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4 ⁺ T lymphocytes," Proc. Natl. Acad. Sci. USA 96: 2982-2987 (1999) | | | |
| <i>PK</i> | DC | Pak et al., "Cloning of the growth factor gene from vaccinia virus LIVP strain in <i>Escherichia coli</i> cells," Mol Gen Mikrobiol Virusol Sept-Oct; (9-10):19-21 (1992) [article in Russian, English summary on last page of article] | | | |
| Examiner Signature | | Date Considered | | | |
| <i>Robert A. Kelly</i> | | 6/2/06 | | | |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 809; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | |

| | | | | | |
|---|--------------|--|--|---|-------------------------------|
| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | | Attorney's Docket No. 17248-004002/4804B | Application No. 10/849,664 |
| List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | | | | Applicant Aladar A. Szalay et al. | |
| | | | | Filing Date May 19, 2004 | Group Art Unit 1632 1633 |
| Other Documents (include Author, Title, Date, and Place of Publication) | | | | | |
| Examiner Initial | Desig. ID | Document | | | |
| <i>RLK</i> | DD | Pan et al., "Regression of Established B16F10 Melanoma with a Recombinant <i>Listeria monocytogenes</i> Vaccine," Cancer Research 59:5264-5269 (1999) | | | |
| | DE | Peplinski et al., "In vivo gene therapy of a murine pancreas tumor with recombinant vaccinia virus encoding human interleukin-1beta," Surgery 118:185-191 (1995) | | | |
| | DF | Phillips-Jones, M.K., "Bioluminescence (<i>lux</i>) expression in the anaerobe <i>Clostridium perfringens</i> ," FEMS Microbiology Letters 106: 265-270 (1993) | | | |
| | DG | Phillips-Jones, M.K., "Use of <i>lux</i> reporter system for monitoring rapid changes in α -toxin gene expression in <i>Clostridium perfringens</i> during growth," FEMS Microbiology Letters 188: 29-33 (2000) | | | |
| | DH | Poptani et al., "Monitoring thymidine kinase and ganciclovir-induced changes in rat malignant glioma <i>in vivo</i> by nuclear magnetic resonance imaging," Cancer Gene Ther 5(2): 101-109 (1998) | | | |
| | DI | Prikhod'ko, G. G. et al., "Cloning, Sequencing and Translation Analysis of the Vaccinia Virus L1VP HindIII N Fragment," Genetika 27(6): 955-963 (1991) [article in Russian, English summary on last page of article] | | | |
| | DJ | Prikhod'ko, G. G. and IV Babkin, "5'-variable genome sequence of vaccinia virus L1VP. Possible role of short direct repeats in formation of DNA deletions," Genetika 27(1): 13-26 (1991) [article in Russian, English summary on last page of article] | | | |
| | DK | Qazi et al., "Real-time monitoring of intracellular <i>Staphylococcus aureus</i> replication," J Bacteriol. 186(4): 1065-1077 (2004) | | | |
| | DL | Rocchetta et al., "Validation of a Noninvasive, Real-Time Imaging Technology Using Bioluminescent <i>Escherichia coli</i> in the Neutropenic Mouse Thigh Model of Infection," Antimicrobial Agents and Chemotherapy 45(1): 129-137 (2001) | | | |
| | DM | Sakamoto et al., "Antitumor effect of normal intestinal microflora on Ehrlich Ascites tumor," Jpn. J. Cancer Res. (Gann) 79: 109-116 (1988) | | | |
| | DN | Scholl et al., "Recombinant Vaccinia Virus Encoding Human <i>MUC1</i> and <i>IL2</i> as Immunotherapy in Patients with Breast Cancer," J. Immunother 23(5): 570-580 (2000) | | | |
| | DO | Shchelkunov et al., "The gene encoding the late nonstructural 36K protein of vaccinia virus is essential for virus reproduction," Virus Research 28: 273-283 (1993) | | | |
| | DP | Shimizu et al., "Antitumor activity of marine bacteria, <i>vibrio anguillarum</i> , in mice," Gann 70: 429-433 (1979) | | | |
| | DQ | Shimizu et al., "Antitumor activity of 2-keto-3-deoxyoctonate-free lipopolysaccharide of <i>vibrio anguillarum</i> in mice," Gann 74(2): 279-284 (1983) | | | |
| | DR | Studený et al., "Bone Marrow-derived Mesenchymal Stem Cells as Vehicles for Interferon- β Delivery into Tumors," Cancer Research 62: 3603-3608 (2002) | | | |
| | DS | Tjuvajev et al., "Noninvasive Imaging of Herpes Virus Thymidine Kinase Gene Therapy and Expression: A Potential Method for Monitoring Clinical Gene Therapy," Cancer Res 56(18): 4087-4095 (1996) | | | |
| | DT | Tjuvajev et al., "Imaging the Expression of Transfected Genes <i>in Vivo</i> ," Cancer Res. 55(24): 6126-6132 (1995) | | | |
| | DU | Tjuvajev et al., "Imaging Adenoviral-mediated Herpes Virus Thymidine Kinase Gene Transfer and Expression <i>In Vivo</i> ," Cancer Research 59: 5186-5193 (1999) | | | |
| <i>RLK</i> | DV | Tjuvajev et al., "Imaging Herpes Virus Thymidine Kinase Gene Transfer and Expression by Positron Emission Tomography," Cancer Res. 58(19): 4333-4341 (1998) | | | |

| | |
|--|---------------------------|
| Examiner Signature <i>Robert A. Kelly</i> | Date Considered 6/2/06 |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP §509; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |

| | | | | | |
|---|--------------|---|--|---|-------------------------------|
| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | | Attorney's Docket No. 17248-004002/4804B | Application No. 10/849,664 |
| List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | | | | Applicant Aladar A. Szalay et al. | |
| | | | | Filing Date May 19, 2004 | Group Art Unit 1632 1633 |
| Other Documents (Include Author, Title, Date, and Place of Publication) | | | | | |
| Examiner Initial | Desig. ID | Document | | | |
|  | DW | Vogt et al., "Untersuchungen über die Möglichkeit der Tumorlokalisation in vivo auf ser Basis eines szintigrafischer Klostridienstäbchen-Nachweises mit ¹³¹ J-markierten Antikörpern und F(ab') ₂ -Antikörperfragmenten," Zeitschrift für Experimentelle Chirurgie 12(4): 209-215 (1979) [article in German, English summary on the last page of the article] | | | |
|  | DX | Volm et al., "Enhancement of Incorporation of ¹³¹ Iododeoxyuridine into Tumors after Application of <i>Clostridium oncolyticum</i> s. <i>butyricum</i> (M 55)," Eur. J. Nucl. Med. 2(2): 117-120 (1977) | | | |
| | DY | Xie et al., "Adenovirus-mediated Tissue-targeted Expression of a Caspase-9-based Artificial Death Switch for the Treatment of Prostate Cancer," Cancer Research 61: 6795-6804 (2001) | | | |
| | DZ | Yang et al., "Visualizing gene expression by whole-body fluorescence imaging," PNAS 97(22): 12278-12282 (2000) | | | |
|  | EA | Zhao et al., "Spatial-temporal imaging of bacterial infection and antibiotic response in intact animals," Proceeding of the National Academy of Sciences 98(17): 9814-9818 (2001) | | | |
|  | EB | Zinoviev et al., "Identification of the gene encoding vaccinia virus immunodominant protein p35," Gene 147: 209-214 (1994) | | | |

| | |
|---|---------------------------|
| Examiner Signature  | Date Considered 6/2/06 |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | |